Surgery with total disc replacement compared to rehabilitation in patients with chronic low back pain and degenerative disc disease : clinical, health economical and biomechanical perspectives by Johnsen, Lars Gunnar
Surgery with Total Disc 
Replacement Compared to 
Rehabilitation in Patients with 
Chronic Low Back Pain and 
Degenerative Disc Disease
Clinical, Health Economical and 
Biomechanical Perspectives
Thesis for the degree of Philosophiae Doctor
Trondheim, February 2014
Norwegian University of Science and Technology
Faculty of Medicine
Department of Neuroscience
Lars Gunnar Johnsen
NTNU
Norwegian University of Science and Technology
Thesis for the degree of Philosophiae Doctor
Faculty of Medicine
Department of Neuroscience
© Lars Gunnar Johnsen
ISBN 978-82-326-0084-7 (printed ver.)
ISBN 978-82-326-0085-4 (electronic ver.)
ISSN 1503-8181 
Doctoral theses at NTNU, 2014:80
Printed by NTNU-trykk
1 
 
Kirurgi med skiveprotese sammenlignet med multidisiplinær rehabilitering.  
En randomisert, prospektiv multisenterstudie. 
 
Denne avhandlingen er basert på en sammenlignende studie av to behandlingsalternativer for 
pasienter med degenerativ skivelidelse i korsryggen og kroniske lave ryggsmerter. Kroniske 
ryggsmerter utgjør et betydelig helseproblem. På global basis er det anslått at 10 % av alle leveår 
med funksjonstap pga ikke-fatal sykdom skyldes ryggsmerter. Mange behandlingsformer har 
vært foreslått men det hersker fortsatt stor uenighet om hva som skal være standard 
behandling. Flere kirurgiske behandlingsalternativer eksisterer. Skiveprotesekirurgi med fjerning 
av mellomvirvelskiven og innsetting av skiveprotese tar sikte på å bevare bevegeligheten i de 
affiserte degenerative segmentene til forskjell fra standard kirurgisk behandling som er 
avstivning. Sammenlignende studier mellom protesekirurgi og avstivningskirurgi har vist omtrent 
like resultater. En del studier har sammenlignet avstivningskirurgi mot ikke-kirurgisk behandling. 
Noen av disse studiene viser best effekt med kirurgi mens andre viser best effekt med ikke 
kirurgisk behandling. Vår studie er den første som sammenligner skiveprotesekirurgi mot et ikke-
kirurgisk behandlings alternativ. 
Rammen rundt studien var en randomisert kontrollert multisenterstudie med 173 pasienter 
rekruttert fra ryggpoliklinikkene ved alle fem universitetssykehus i Norge. Pasientene ble 
randomisert enten til kirurgi med innsetting av skiveprotese eller til et ikke-kirurgisk 
behandlingsopplegg i form av tverrfaglig (multidisiplinær) ryggrehabilitering. Oppfølgingstiden 
etter primærbehandlingen var 2 år med kontroll etter 6 uker, 3, 6, 12 og 24 måneder. En rekke 
kliniske utfallsmål ble brukt med ODI (Oswestry Disability Index) som hovedeffektvariabel i en 
klinisk og en biomekanisk studie og EQ-5D som effektvariabel i en helse økonomisk studie. To år 
etter oppstart av primærbehandlingen ble alle pasienter i tillegg undersøkt og vurdert av to 
uavhengige observatører blindet for behandlingstype. 
Vi konkluderer med at både kirurgi med skiveprotese og ikke kirurgisk behandling med 
multidisiplinær rehabilitering gir signifikant bedring i livskvalitet etter 2 år hos selekterte 
pasienter med kroniske ryggsmerter og degenerativ mellomvirvelskive. Bedringen var størst i 
kirurgi gruppen men selv om forskjellen mellom behandlingsgruppene var statistisk signifikant, 
så var den ikke sikkert klinisk signifikant. Samtidig viser vi at det sannsynligvis er andre 
egenskaper ved protesen enn bevegelighet som bidrar til denne (signifikante) bedringen av 
livskvalitet. Videre er det usikkert om skiveprotesekirurgi vil være et kostnadseffektivt alternativ 
til ikke kirurgisk behandling da kostnadseffektiviteten i denne studien var svært avhengig av 
hvilken livskvalitetsindeks som ble brukt som effektmål. I en analyse av noen sentrale 
psykometriske egenskaper ved disse indeksene konkluderer vi med at det er stor forskjell 
mellom dem, at de ikke kan brukes om hverandre og at valg av indeks som effektmål i kost-
effekt studier generelt sannsynligvis bør relateres til diagnose og/eller behandlingstype.  
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DEFINITIONS AND KEY CONCEPTS 
 
Total disc replacement (TDR): a standardised surgical technique where an intervertebral disc of 
the spinal column is removed and replaced with an artificial implant, a prosthesis. 
 
 Multi-disciplinary rehabilitation (MDR): a structured education programme (often with varying 
content) consisting of group-based training covering topics of anatomy, physiology (including 
pain), and illness, as well as exercises and training. The aim is to increase patient functioning and 
coping ability1. 
 
Patient-reported outcome (PRO): questionnaires filled out by patients to evaluate the outcome 
of a treatment. The questionnaire assesses a single underlying characteristic – a measurement of 
the health state of the patient that may or may not be of concern to the patient. The 
measurement characteristic is termed a ‘construct’ and the questionnaires used to collect them 
are called ‘instruments’. When a questionnaire measures a single construct it can be said to be 
unidimensional. 
 
Quality-adjusted life year (QALY): a method used to calculate how many extra months or years 
of life of a reasonable quality a person might gain as a result of treatment. The advantage of 
using QALYs to measure the effect of treatment(s) is that it allows comparisons across disease 
areas. One disadvantage is that the use of generic instruments to measure quality of life as 
opposed to disease-specific instruments could be inaccurate and less responsive to a change in 
health state (e.g., after treatment). 
Cost-utility analysis (CUA): a method of combining economic and clinical effect (outcome) to 
evaluate treatment of a disease. The cost of the treatment (hospital costs, follow-up costs, social 
expenditures, etc.) is combined with PROs in the form of a generic quality of life questionnaire, 
which is then transformed to give a scale value from 0 (dead) to 1 (excellent health) and which, 
combined with time, gives the unit ‘QALY’.   
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Distortion-compensated Roentgen analysis (DCRA): a method for evaluating sagittal plane 
motion, translation, and disc height in segments of the spinal column from plain lateral 
radiographic views. The method compensates for distortion in central projection, off-centre 
position, axial rotation, and lateral tilt of the spine. The method also comprises a database of 
disc height, vertebral height, and sagittal plane displacement from lateral radiographic views of 
the lumbar spine, valid for male and female subjects in the age range of 16–57 years and used as 
a norm reference in the assessment of sagittal motion and disc height. 
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SUMMARY 
The subject of this thesis is a comparative study of two treatment options for a selected group of 
patients with degenerative disc disease and chronic low back pain. Chronic low back pain 
represents a significant health problem. Globally, it is estimated that 10% of all years with 
functional impairment due to non-fatal disease is caused by low back pain. Many types of 
treatment have been proposed but there is still great disagreement about what should be the 
standard treatment. Several surgical treatment options exist. Disc arthroplasty with removal of 
the intervertebral disc and the insertion of a disc prosthesis aims to preserve the mobility of the 
affected degenerative segments. This is different to standard surgical treatment, which is fusion 
of the affected segments. Comparative studies of arthroplasty and fusion surgery have shown 
approximately even results. Other studies have compared fusion surgery against non-surgical 
treatment. One of these studies showed the best effect with surgery while others showed no 
difference. Our study is the first to compare disc replacement surgery with a non-surgical 
treatment option. 
The setting for the study was a randomised controlled multicentre trial including 173 patients 
recruited from outpatient back clinics at all five university hospitals in Norway. Patients were 
randomised either to surgery with the insertion of a disc prosthesis or to a non-surgical 
treatment option in the form of (multi-disciplinary) spinal rehabilitation (MDR). Follow-up time 
after primary treatment was 2 years, with control after 6 weeks and 3, 6, 12, and 24 months. A 
variety of clinical outcome measures were recorded at the controls with the Oswestry Disability 
Index (ODI) as the primary endpoint in a clinical and in a biomechanical study and EuroQol 5D 
(EQ-5D) and Short Form-6D (SF-6D) as the effect variables in a health economic study. Two years 
after the index treatment, all patients were, in addition, examined and evaluated by two 
independent observers blinded to treatment type. 
In the first study, we found that surgery with the insertion of a disc prosthesis after 2 years 
resulted in a statistically significantly better outcome compared with the non-surgical treatment 
in most clinical outcome measures including the primary efficacy variable. However, this 
difference could not be said to be clinically significant.  
In the second study, we looked at the health economic consequences of choosing disc 
arthroplasty over a non-surgical treatment option. We found that it is uncertain if total disc 
replacement (TDR) could be a cost effective alternative to MDR. When the EQ-5D was used, TDR 
was cost effective, but when the SF-6D was used, it was not. 
14 
 
The main purpose of inserting a disc prosthesis is to preserve movement of the segments. This 
was the subject of a third study. We found no significant difference in segmental motion in the 
operated segments compared with segments at the corresponding level in the non -operated 
group. Furthermore, we found no relationship between segmental movement and disc height 
after the insertion of a disc prosthesis and clinical outcomes.  
In the fourth study, we investigated some of the key psychometric characteristics of the EQ-5D 
and the SF-6D used as efficacy measurements in the health economic study. We found that 
there were significant differences between these indices in terms of ability to detect change 
after treatment and that, even though they measure the same construct along the same (overall 
quality of life) numeric scale, they measure different aspects of this property. 
We conclude that surgery with disc prosthesis and non-surgical treatment in the form of MDR 
provide significant improvement in quality of life after 2 years in selected patients with chronic 
low back pain and degenerative disc disease. The improvement was greatest in the surgical 
group. Although statistically significant, the difference between treatment groups could not be 
said to be clinically significant. At the same time, we showed that there were probably other 
characteristics of the prosthesis than segmental mobility that contributed to this (significant) 
improvement in quality of life after 2 years. Moreover, it is uncertain whether disc replacement 
surgery would be a cost-effective alternative to non-surgical treatment, as cost effectiveness in 
this study was highly dependent on the quality of life index used as an outcome measure. In an 
analysis of some key psychometric properties of these indices, we conclude that there is a big 
difference between them, that they are not interchangeable, and that the choice of index in 
cost-effectiveness studies, in general, probably should be related to diagnosis and/or treatment 
type. 
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1 INTRODUCTION 
 
1.1 Epidemiology 
The lifetime incidence for an episode of low back pain (LBP) has been estimated to be about 80% 
and the prevalence of chronic low back pain (CLBP) is about 23%2-4. In a systematic review of the 
literature by Hoy et al5, estimates of the point prevalence of LBP ranged from 1.0% to 58.1% 
(mean: 18.1%; median: 15.0%), and 1-year prevalence from 0.8% to 82.5% (mean: 38.1%; 
median: 37.4%)5. The Global Burden of Disease report from 2010 states that LBP constitutes 
10.7% of total global years lived with disability (YLD) and it is ranked as the 9th of the 50 most 
common global sequelae of diseases6.  
In Norway, the point prevalence has been reported to be 13.4%, the 1-year prevalence 40.5%, 
and the lifetime prevalence 60.7%7. Furthermore, back pain was ranked as the most common 
type of health problem among individuals of 15–74 years of age with work-related health 
problems in Norway in 2007 (Statistics Norway 2011). The prevalence of back pain-related 
problems reported here was 27.1%, with pain in the shoulder and neck in second place with 
19.4%. After 2 years’ absence from work because of LBP, the likelihood of returning to ordinary 
work is less than 1% which, in turn, has a great influence on the size of social security payments8.  
Walsh9 found a rise in low back disability between the ages 20 to 29 and 30 to 39 and then it 
remained constant up to age 50 to 59. Several authors have reported an increase in LBP 
prevalence10-13. It has been suggested that part of this increase was a result of the transition 
from an agrarian to an industrial society that took place at the end of the 19th century and 
Waddell11,14 states in a paper from 1987 that “…low back-disability as opposed to pain is a 
relatively recent Western epidemic”. The combination of modern diagnostic modalities and 
improved social support that allows for absence from work without catastrophic economic 
consequences could at least partly explain this increase4,14,15. Harkness et al16 mentioned 
increasing rates of psychological distress and increased awareness of certain pain syndromes, 
not only by patients but also by health professionals as possible explanations. 
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1.2 Degenerative Disc Disease  
1.2.1 The normal disc 
The main function of the intervertebral disc (IVD) is to act as a shock absorber and to maintain 
limited mobility of the spine17,18. Three morphologically distinct structures can be identified18: a) 
a thick outer ring of fibrous cartilage termed the annulus fibrosus (AF), organised in a series of 
15–25 concentric rings or lamellae19; b) a gelatinous core termed the nucleus pulposus (NP), 
consisting of randomly organised collagen fibres and elastin fibres surrounded by the AF20,21; and 
c) the vertebral end plates at the top and bottom of the vertebrae, inferior and superior to the 
AF and NP. The end plates consist of a thin horizontal layer, usually less than 1 mm thick, of 
hyaline cartilage18,22. In the healthy IVD, the end plate is usually an avascular and aneural 
structure18,23,24.  
1.2.2 The degenerative disc 
A central concept in understanding disc degeneration is nutrition for the disc22-25. There is strong 
evidence that a fall in nutrient supply is associated with disc degeneration23. Discs receive most 
of their nutrients by diffusion through pores in the vertebral end plate from capillaries at the 
margin of the end plate18,23,26-28. Steep differences in concentrations of glucose, oxygen, and 
lactic acid provide an exchange of nutrients and waste metabolites into and out of the matrix of 
the cells in the NP across these pores23. It has been documented that cyclic mechanical stimuli in 
the form of compression and decompression assist in the exchange of large soluble factors 
across the IVD and its surrounding circulation and apply direct and indirect stimulus to disc 
cells29. Proteoglycans are huge water-binding molecules in the extracellular matrix of the disc. 
Aggrecan, a highly anionic glycosaminoglycan and a major proteoglycan especially in the NP, is 
responsible for maintaining tissue hydration through osmotic pressure30. Because of its 
structural alignment, resistance of compression of the disc is essential31. The hydrophilic 
properties of proteoglycans cause the NP to swell which, in turn, increases the resistance to 
compressive forces32. During growth and with increasing age, obliteration of the pores of the 
end plate by calcification and/or diminished blood supply to the IVD causes diminished nutrition 
flow to matrix cells 23. This initiates tissue breakdown23,33. There is a fine balance between 
synthesis, breakdown, and accumulation of matrix macromolecules18. This delicate balance is 
influenced by proteinases and other enzymes34,35. Much research of recent years has been done 
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to clarify the role of such enzymes, especially the metalloproteinases. It is now commonly 
accepted that their proteolytic action in degradation, especially of aggrecan, plays a central role 
in DDD throughout life30,36-38. The degradation of proteoglycans causes damage of major 
structural components of the IVD38,39. In vitro studies have shown that metalloproteinases may 
be produced by cells of the discs themselves as well as by cells of the invading blood vessels; the 
invasion takes place as a part of the degenerative process18. The loss of matrix production of 
proteoglycans including aggrecan and, at the same time, an increase in matrix degradation lead 
to loss of the water-binding ability of the proteoglycans, which causes the nucleus to be less 
hydrated23,24,40. When fluid pressure within the disc falls, the disc starts bulging radially as a 
result41. The regularity of the annular lamellae is also compromised and the degenerate disc 
becomes increasingly cracked and fissured42. The disarrangement of the cartilaginous tissue 
structure of the disc eventually leads to loss of both disc height and biomechanical properties 
such as shock absorption and flexibility in movement17,18. The structural failure associated with 
degenerative changes may also cause spinal instability, which has been considered as one of the 
significant causes for mechanical LBP43. 
Adams proposed a definition of disc degeneration as “…an aberrant cell-mediated response to 
progressive structural failure”54. As possible causes for this structural failure of the IVD, he 
mentioned genetic inheritance, age, inadequate metabolite transport, and loading history. 
1.2.3 Genetic factors for DDD 
Several studies have documented the family aggregation of lumbar disc disease44-48. Heredity 
and linkage studies have demonstrated the correlation between genetics and IVD pathology. 
From the presence of family aggregation of DDD follows the possibility of the influence of a 
genetic component49. A differentiation between genetic factors and social-behaviour factors is, 
however, necessary. This has been achieved to a certain degree through twin studies. In a 
Finnish study based on in-depth interviews of twins and magnetic resonance imaging (MRI) 
scans, Battie et al50 were able to show that 77% of the variability in disc degeneration 
observation scores could be explained by family aggregation. However, the authors stressed the 
fact that such studies could not separate genetic, anthropometric, and metabolic factors and the 
effect of shared early environment and lifestyle influences. In a study of twins unselected for 
back pain, Sambrook et al51 were able to show that overall heritability for lumbar disc 
degeneration was 74%. In a UK twin study, Livshits et al52 showed that one of the main risk 
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factors for reported episodes of severe and disabling LBP was genetic heritability. McGregor et 
al53 reported a significant genetic effect on LBP, with estimates of heritability ranging from 52% 
to 57%. 
Genetic studies on DDD have focused on the genes that code for functioning molecules in the 
disc49. These include aggrecan, degrading enzymes such as metalloproteinase II, and signalling 
molecules such as Interleukin I (IL-1), known to stimulate nerve endings on nociceptive nerve 
fibres49,54,55. An example on how genetic research may be useful in the treatment of DDD is the 
work of Sudo et al56. They showed how knowledge of the regulatory mechanism of the 
molecular response of NP cells to nutrient deprivation might reveal a new strategy for treating 
disc degeneration. It is important to remember the fact that it is not a single gene but interaction 
between genes that contributes to DDD57. 
Because genetic factors may interact with environmental factors, several authors emphasised 
the point that studies on genetic factors should include analysis of the interaction between 
genetic, behavioural, and environmental factors49,58,59. Battie60, one of the authors of many 
Finnish twin studies, concluded in a relatively recent study that genetic and environmental 
influences on disc degeneration seemed to be of similar importance.  
 
1.3 LBP and DDD 
1.3.1 Possible pathophysiological mechanism for LBP from DDD 
The sensory pathways of the IVD follow a dual pattern61. One route enters the adjacent dorsal 
root segmentally, whereas the other supply is non-segmental and ascends through the 
paravertebral sympathetic chain with re-entry through the thoracolumbar white rami 
communicantes. In the healthy IVD, only the outer third of the AF is innervated. Coppes62 
described a more extensive disc innervation in the severely degenerated human lumbar disc 
compared with the normal discs and it has been postulated that this neural ingrowth into the 
IVD is an important factor in discogenic LBP63,64. Freemont et al65 were able to show that 
nociceptive nerve fibres grew into the inner third of the annulus. Some of these fibres contained 
neuropeptides, which are associated with nociception62,64,66,67. Degenerative discs are known to 
produce high levels of pro-inflammatory mediators like interleukin-6 (IL-6), interleukin-8 (IL-8), 
and prostaglandin E2 (PGE2)68. These inflammatory and pro- inflammatory mediators from the 
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diseased degenerative tissue are thought to sensitise nerve endings of the nociceptive nerve 
fibres, and the inflammatory response is thought by many to be the main pathophysiological 
cause of CLBP from DDD64,68-72.  
During the degenerative process and break down of disc structure, the IVD segment becomes 
unstable 43. The excessive motion following this process is thought to cause pain because of the 
stretching and compressing of structures like ligaments, joint capsules, annular fibres, or end 
plates, which are known to have a significant number of nociceptors43. 
It is now generally agreed that degenerated IVDs are a major tissue source in CLBP73-75. However, 
the phenomenon of central sensitisation has to be taken into consideration74. Nociceptive 
stimuli from the degenerated IVD are transmitted via the spinothalamic tract to the cerebral 
cortex and C-fibres fire repetitively to the dorsal horn76. Over time, this constant firing of 
neurons causes increased excitability in cell membranes of the central nervous system77. This 
generates pain hypersensitivity and the pain is no longer coupled solely to the peripheral 
nociceptive tissue source, the IVD in this case, but also to the hyper excitable neuron cells of the 
central nervous system77.  
1.3.2 The biopsychosocial model 
Waddell50,78 proposed a biopsychosocial model of LBP. In this model, pain is basically thought of 
as physiological. However, according to Waddell’s model, the whole process of experiencing 
chronic pain may be modified by psychological factors such as the patient’s personality and pre-
existing psychological state. Factors like social environment, illness behaviour, psychological 
distress, attitudes, and beliefs can, in this model, at least partly explain the patient’s current 
level of pain and disability. This can modulate the process of central sensitisation. Other authors 
have later reported on emotional or cognitive regulation of pain, confirming the biopsychosocial 
model79,80. The model is important for the rationale of treatment of LBP with a cognitive 
approach. 
1.3.3 Environmental factors for LBP 
LBP affects between 14% and 80% of working age people, depending on case definition81. 
Specific occupational physical activities that have been associated with LBP include heavy 
manual work, lifting and twisting, postural stress, and whole body vibration50.  
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Occupational activities like bending/twisting, awkward postures, sitting, standing/walking, 
carrying, pushing/pulling, lifting and manual handling/assisting patients have an uncertain 
strength of relationship to LBP81-85. Harkness86, in a study of risk factors for new-onset LBP 
amongst newly employed workers, concluded that several aspects of the workplace 
environment, other than mechanical factors, were important in predicting new-onset LBP. 
Jørgensen et al84 discussed some of the main critiques of existing studies on the relationship 
between physical work demands and musculoskeletal pain. They mentioned potentially 
confounding factors like individual and socioeconomic factors in addition to the predominant 
use of self-reported measurements of physical work demands, which have been shown to have 
poor validity.  
1.3.4 Individual risk factors for LBP 
LBP increases with age but the dose-response relationship between age and LBP is not linear, 
suggesting that multiple factors are involved87,88. Causes of severe back disorders have been 
found to be clustered around a subject's socioeconomic status, indicated by formal 
education89,90. Low job control or satisfaction can increase the risk of hospitalisation for back 
disorders50,89. Smoking was found to be associated with LBP, but the results could be difficult to 
interpret because of linkage to social class, education, and occupation50,91,92. Obesity and being 
overweight increase the risk of LBP93. An association of atherosclerosis with LBP and the degree 
of disc degeneration was found in some studies94-97. Studies of Linton98,99 indicated that 
psychological factors like psychological distress (odds ratio=13.2) and poor function (odds 
ratio=6.4) were associated with a greater risk of developing back pain than perceived workload, 
gender, and foreign birth.  
In conclusion, studies have shown a correlation between LBP and DDD, although the strength of 
this association remains unclear 81,100-102. Studies that have attempted to identify possible risk 
factors for LBP found genetic, vascular, work-related, and lifestyle-related causes. At present, the 
common explanation is that the cause of the problem of CLBP is multifactorial (Fig. 1) and that 
evaluation of patients with DDD and LBP should aim at identifying underlying psychosocial 
factors as well as biological factors 57,74,103-105.  
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Figure 1.  Possible pathogenesis of discogenic low back pain. Adapted from Zhang YG, Guo TM, Guo X, Wu 
SX. Clinical diagnosis for discogenic low back pain. International journal of biological sciences 2009;5:647-58. 
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1.4 Classification and clinical presentation 
It is common to distinguish between specific and nonspecific back pain. Approximately 15% of 
LBP incidences can be related to a specific cause such as fracture, malignant disease, or 
rheumatic disorders106. The Norwegian guidelines for the diagnosis and treatment of LBP1 
recommend an internationally recognised tripartite division of clinical symptoms: a) nonspecific 
LBP; b) LBP with affection of nerve root/nerve root pain; and c) conditions of LBP with possibility 
of malignant disease or cauda equina affection. The concept of ‘flags’ was introduced to 
categorise seriousness of the disease and prognostic aspects50. Red flags indicate that there 
might be spinal pathology or referred pain to the spinal column, which should prompt the 
clinician to take action immediately. Yellow flags indicate that there might be psychosocial 
causes for LBP and that there is a risk of the development of chronicity. Green flags are factors 
that indicate a good prognosis for rapid spontaneous recovery1,11. The duration of LBP is usually 
divided into acute (0–4 weeks), sub-acute (4–12 weeks), and chronic (more than 12 weeks)107,108. 
The term “long lasting” is preferred over “chronic” by some authors1 focusing on the dynamic 
aspect of treatment. 
 
1.5 Imaging 
Degenerative changes in the spine can be seen in different X-ray modalities like Computed 
Tomography (CT) and plain radiographs. The morphological appearance and biochemical matrix 
composition can be visualised on MRI and several radiological classification systems for DDD 
have been described109,110. Degenerative changes of the IVD in patients eligible for our study 
were classified based on four MRI findings: 
1.5.1 Disc height reduction 
Some authors reported a correlation between disc height and LBP111-114. Several methods on 
how to measure this have been proposed, using different radiological modalities. Andersson115 
noted that accurate measurements could not be obtained from routine roentgenographs. 
Raininko116 reported fair to excellent intra-observer agreement on MRI scans. Frobin117,118 
compared the height of lumbar discs measured from radiographs with the height classified from 
MRI images in a cross-sectional study using the DCRA method when assessing radiographs. He 
found that loss of disc height on MRI images was compatible with radiographs on average, 
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although imprecise in the assessment of individual discs117. In conclusion, disc height is a 
common finding in DDD but shows a weak-to-moderate association with LBP119. 
 
1.5.2 Modic changes 
In 1988, Modic et al120 reviewed 474 patients referred for lumbar spine MRI. On the basis of this 
study, they proposed a classification of degenerative changes in the lumbar vertebral bone 
marrow.  In comparison with histopathological findings, they observed that the signal intensity 
changes appeared to reflect a spectrum of vertebral body marrow changes associated with DDD. 
Their classification has become the most common system for the classification of degenerative 
changes in the lumbar spine. 
 
Table 1.  From Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR. Degenerative disk disease: 
assessment of changes in vertebral body marrow with MR imaging. Radiology 1988;166:193-9. 
Modic type MRI findings Histopathological findings 
Type 1 Reduced signal intensity on T1-weighted spin-
echo images and increased signal intensity on 
T2-weigthed images 
Disruption and fissuring of the 
end plates, vascularised fibrous 
tissue 
Type 2 Increased signal intensity on T1-weighted 
images and isointense or slightly increased 
signal intensity on T2-weighted images 
Yellow marrow (fat) replacement 
of red bone marrow 
Type 3 Reduced signal activity on both T1- and T2-
weighted images 
Osteosclerosis 
 
 
Later, some works have tried to assess the correlation between clinical findings, i.e., LBP and 
Modic changes on MRI. Braithwaite et al121 evaluated pain correlation between lumbar 
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discography and Modic changes. They found that Modic changes appeared to be a relatively 
specific but insensitive sign of a painful lumbar disc in patients with LBP. Luoma et al122 found an 
increased risk of LBP (including all types) in relation to all signs of disc degeneration. Kjaer et al123 
found that patients with degenerative discs and at the same time Modic changes in the vertebra 
had a distinct clinical profile different from that of patients with degenerative disc only. They 
concluded that LBP and Modic changes were strongly correlated and that people with both DDD 
and Modic changes might deserve to be diagnosed as having specific LBP. Cheung124 concluded 
that disc degeneration was strongly associated with back pain in a dose-related manner based 
on MRI findings.  
1.5.3 High-intensity zone 
Disruption of the inner AF in the form of radial fissures as a result of the degenerative process 
can be visualised on MRI scans. Because of their appearance on MRI, such degenerative changes 
are called high-intensity zone(HIZ) 125,126. Such changes have been found to correlate with LBP in 
patients with DDD and it has been suggested that the outer annular disruption is painful124-128. In 
a study published in 1991, Aprill and Bogduk125 assessed the prevalence, reliability, and validity 
of this sign in 500 patients undergoing MRI for back pain. HIZ occurred in 28% of the patients 
with back pain and the positive predictive value was 86%. Later, several authors reported on the 
correlation between lumbar discography, pain reproduction, and HIZ findings on MRI126,128-130. 
While Lam et al129 found that the sensitivity, specificity, and positive predictive value for pain 
reproduction were high (81%, 79%, and 87%, respectively), Carragee131,132, in a study of 2000 
patients, concluded that although the prevalence of HIZ was slightly higher in symptomatic 
patients, the prevalence in asymptomatic individuals with DDD (25%) was too high for 
meaningful clinical use of this sign.  
In conclusion, HIZ on MRI occur frequently in patients with LBP. The presence of HIZ is thought 
to be an indicator for LBP with a high sensitivity and low specificity69. 
1.5.4  Morphological changes in the disc 
Morphological changes in the disc can be assessed by signal intensity of the NP in addition to 
anterior and posterior bulge of the IVD, and have been associated with nonspecific LBP133,134. 
The decrease in proteoglycan content and subsequent loss of water content result in reduced 
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signal intensity on T2-weighted MRI135,136. Relative signal intensity of the NP in the relation to the 
signal intensity of the cerebrospinal fluid can be calculated to assess the degree of disc 
degeneration137. Luoma134 classified the signal intensity as: 1=Bright; 2=Grey; 3=Dark; and 
4=Black, with an inter-observer agreement (weighted kappa) in the range of 0.59–0.83 and an 
intra-observer agreement rate of 57% to 81%.   
In summary, although MRI can act as a tool for basic research into disc physiology and the 
aetiology of disc degeneration, studies on MRI have only been able to establish a weak 
correlation between progressive disc degeneration and LBP development24. Degenerative 
changes have been found in symptomatic as well as asymptomatic people119,133,138,139. In our 
study, we assessed the reliability of MRI findings in candidates for TDR140.  Inter-observer 
agreement here was generally moderate or good. 
 
1.6 Treatment 
1.6.1 Surgery for LBP 
Hibbs and Albee 141 (in 1911) and Chandler 142 (in 1929) were the first to report a surgical 
technique with the intention to produce a fusion between the posterior aspects of the spinal 
vertebrae. The indication for surgery at that time was Pott’s disease (tuberculosis of the spine). 
Howorth143 (in 1937) was the first to use fusion surgery in conjunction with a ruptured NP. 
Barr142,143 (in 1947) wrote that the unpredictable results of LBP after disc excision operation was 
the result of underlying structural weakness of the disc and recommended spinal fusion together 
with disc excision, the “combined operation”144,145. 
During the 70s and 80s, fusion surgery gained increasing recognition and, between 1996 and 
2001, the annual number of spinal fusion operations in the United States rose by 77%146. 
Implants for spinal fusion with pedicle screws became almost supreme in the market. In 1998, 
the annual rate for spinal lumbar fusion in the United States reached 77 628 which increased to 
210 407 in 2008147. Deyo148 mentioned as possible explanations for this changes in the 
population, technological advances, uncertainty regarding indications, as well as the financial 
incentives for surgeons, hospitals, and the device industry, which may have had synergistic 
effects.  
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Several randomised studies in recent years have shown that fusion surgery has a certain effect 
on the patients’ pain and function149 and it has been compared with non-operative treatment. In 
a Swedish study of 294 patients, Fritzell et al150 concluded that fusion surgery compared 
significantly better than care as usual (mainly physical therapy) with respect to health-related 
quality of life (HRQoL; assessed by the ODI), pain, and net back to work. Brox et al151,152, in two 
randomised controlled trials, found no significant difference in ODI between fusion surgery and a 
multi-disciplinary treatment regime similar to that used in our study. In an English randomised 
controlled trial from 2005, no significant difference in ODI between fusion surgery and an 
intensive rehabilitation programme similar to Brox was found153.  
Fusion surgery requires healing and stabilising of the spinal musculature postoperatively as well 
as healing of bone and there is a certain percentage of non-union 154. 
 
TDR surgery – ‘the long quest for mobility’ 
Arthrodesis – the process of surgical fusion of a joint – is generally not considered an optimal 
solution, due to the increased stresses and subsequent degeneration in the adjacent joints155. 
This fact led to the introduction of arthroplasty in the hip as an alternative to arthrodesis early in 
the 60s, which has had a great impact on quality of life for patients with coxarthrosis 155-158.  
In the spine, it has been claimed that the fusion of segments leads to biomechanical changes 
that bring about increased degeneration by superimposing stress on neighbouring segments, a 
phenomenon called adjacent level disease (ALD)159-161. Alteration of the biomechanics in the 
adjacent segments has been demonstrated by several authors 162,163.  It has been claimed that 
this occurs in addition to the painful excessive motion of the degenerate IVD mentioned 
before43.  
The incidence of symptomatic ALD was reported to be in the range of 5.2 to 18.5%, while the 
incidence of radiographic ALD was in the range of 8 to 100%, suggesting that it is difficult to rule 
out the effect of the age-related natural course of DDD54,160. 
In 1966, the Swedish spinal surgeon Fernström164 presented 191 patients in which he had 
implanted steel balls as a replacement for degenerated discs in order to preserve motion. 
Patients were operated for up to eight segments at a time, but the clinical results were poor. The 
Fernström steel ball illustrated two important aspects of disc prostheses. First, 88% of the 
27 
 
patients developed subsidence after 4 to 7 years, a phenomenon in which the prosthesis, due to 
mechanical wear and tear, drops down into the end plates of the vertebra and eventually into 
the vertebral body142,165,166. Second, adverse biomechanical conditions with instability were 
encountered in the operated spine. A ball that rests against an end plate will have virtually 
infinite degrees of freedom and movement will only be limited by soft tissue. This is non-
physiological and the problem is amplified the more the number of segments operated. The 
failure of the Fernström ball prosthesis brought discredit to the concept of implantation of a 
mobile device after removing the degenerative disc among spinal surgeons. However, the idea of 
a motion-preserving device was not totally left. 
Some devices were patented but did not become a commercial success (Table 2, Fig. 2). Since 
1973, there has been an almost yearly acquisition of a new disc replacement patent, of which 
only a small number have reached clinical use142,167. In the late 80s and early 90s, the French 
spine surgeon Marnay168 began to implant a new type of disc prosthesis with three components, 
called Pro Disk 1. At about the same time, Bütner-Janz et al169 in eastern Germany began to 
implant the Charité prosthesis on a commercial basis. Later, the Maverick prosthesis was 
developed. These are the three most common types of lumbar disc prosthesis today. In the 
lumbar spine, the rationale for introducing a motion-sparing device became the avoidance of the 
junctional degeneration seen after arthrodesis (i.e., fusion surgery), by the preservation of 
segmental motion170. 
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Table 2. Development of disc prostheses and disc substitutes. From Errico TJ. Lumbar disc arthroplasty. Clin 
Orthop Relat Res 2005:106-17. 
Year Inventor(s) Device 
1955 Cleveland, Hamby, and Glaser Acryl substance in the disc space 
1966 Fernström Steel ball after removing the disc 
1974 Froming Fluid-filled elastic chamber sandwiched between 
two metal cup end plates 
1975 Stubstad Dacron mesh containing a silicon disc 
1978 Fassio Silicon prosthesis 
1980s Heller Posteriorly hinged metal prosthesis with 
interposed titanium springs 
1980s Steffee Polyolefin rubber contained between two titanium 
plates (the Acroflex disc) 
1989 Bütner-Janz Charité prosthesis. Metal on plastic 
1989 Marnay ProDisc I prosthesis. Metal on plastic 
2002 Mathews et al Maverick. Metal on metal 
 
 
 
Figure 2. The Buttermann intervertebral prosthetic device from 1998. Patented but never implanted in 
humans. 
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Thus, the theoretical advantages of modern disc arthroplasty are the preservation of motion 
(hence the expression ‘motion-preserving device’), avoidance of trauma of the back muscles (the 
procedure takes place transabdominally), and the lack of need for bone healing171,172. A 
biomechanical classification system for modern TDRs has been proposed (Table 3)171.  
 
Table 3.  Classification of biomechanical properties of modern lumbar intervertebral prostheses. 
Adapted from Errico TJ. Lumbar disc arthroplasty. Clin Orthop Relat Res 2005:106-17. 
1 Constrained The prosthesis has mechanical limitations in the physiological ROM 
2 Semi-
constrained 
The prosthesis has mechanical limitations in certain directions of motion but 
may have freedom of movement beyond the physiological ROM in other 
directions 
3 Unconstrained The prosthesis is mobile beyond the physiological ROM in all directions 
 
To prevent subsidence, modern prostheses have a ‘footprint’, a contact surface against the end 
plate that distributes the axial pressure to avoid subsidence, in addition to restrictions on 
movement in one or more directions 171. Although these motion-sparing devices have different 
designs, two crucial components seem to be common in the expected theoretical mechanism of 
pain relief after TDR142: (1) complete excision of the nucleus and (2) the restoration or 
improvement of normal intervertebral biomechanics171.  
1.6.2 Complications in TDR surgery 
The complication and reoperation rates after implanting a lumbar disc prosthesis are about the 
same magnitude as those reported for fusion surgery173. Common types of complications in the 
two surgical methods include postoperative wound infection, sepsis, and subsidence of implant. 
Specific complications for the anterior access to the spine in order to reach the lower segments 
of the spine are perioperative vascular damage, perioperative intestinal damage, postoperative 
ileus, postoperative retrograde ejaculation, and complications related to the implant174,175. The 
30 
 
risk of injury to the great vessels and retroperitoneal structures is greater during revision than 
primary procedures176.  
1.6.3 Outcome after TDR 
Outcomes after TDR are summarised in a Cochrane paper from 2012177. The study included 40 
publications including seven randomised controlled trials. Although statistically significant, the 
difference between TDR and standard fusion surgery was not beyond generally accepted 
clinically important difference. However, there are indications for less radiological degeneration 
of the adjacent levels with disc prosthesis compared with fusion surgery178-180 although this is 
controversial181.  
1.6.4 Non-surgical treatment 
A variety of non-surgical treatments are described in the literature. Ostelo et al182, in a Cochrane 
review from 2005, referred to three behavioural treatment approaches: operative, cognitive, 
and respondent. Middelkoop et al103 reviewed the effectiveness of physical and rehabilitation 
interventions including exercise therapy, back school, transcutaneous electrical nerve 
stimulation (TENS), low-level laser therapy, education, massage, behavioural treatment, traction, 
multi-disciplinary treatment, lumbar supports, and heat/cold therapy.  
1.6.5 Outcome after non-surgical treatment 
In the review by Middelkoop103, MDR was found to be more effective in reducing pain than no 
treatment and patients receiving behavioural therapy had reduced pain compared with waiting 
list controls. However, none of the studies in this review reached a difference that was defined 
as clinically important and the evidence for effectiveness was low.  
The Cochrane review by Ostelo et al182 concluded that adding behavioural components to usual 
treatment programmes for CLBP (i.e., physiotherapy, back education, or various forms of 
medical treatment) had no significant effect on pain relief either in the short-term or long-term. 
However, patients receiving combined respondent-cognitive therapy and progressive relaxation 
therapy had better short-term pain relief than waiting list controls182.  
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In a meta-analysis of psychological interventions for CLBP, Hoffman et al183 concluded that multi-
disciplinary approaches with a psychological component could have positive short-term effects 
on pain interference and positive long-term effects on return to work compared with active 
control conditions. 
In a randomised controlled trial, Brox et al151 showed equal improvement in back pain, use of 
analgesics, emotional distress, and life satisfaction after treatment with cognitive intervention 
and exercises compared with fusion surgery. In a later study, they reported that lumbar fusion 
failed to show any benefit over cognitive intervention and exercises in patients with CLBP after 
previous surgery for disc herniation152. The non-surgical treatment used in these two studies 
resembled the one used in our study184. 
Overall, a moderate effect of multi-disciplinary treatment is reported in the literature103,182,185. 
Several authors of review studies reported that firm conclusions about the effectiveness of 
different non-surgical treatment options for patients with LBP were hard to draw due to the 
heterogeneity of the populations, interventions, and comparison groups103,183,186. No 
complications have been described for non-surgical treatment of LBP. 
 
1.7 Health economy and LBP 
1.7.1 Health economic consequences of LBP 
From the 1890s when LBP was first reported in the context of compensation until today, there 
has been a dramatic increase in spending on sick leave and disability pension due to back pain 14 
. Frymoyer187 reported in 1991 that although low back disorders were extremely prevalent in all 
societies, it was the rate of disability that had increased and not the frequency of LBP per se for 
the last decades. This was later confirmed by Norwegian authors188. 
The direct and indirect costs associated with LBP in Norway was between 13 and 15 billion 
Norwegian kroner in 2008188 and patients with CLBP are known to have a higher consumption of 
health services than most other groups of patients189,190. Gore et al191 compared comorbidities, 
pain-related pharmacotherapy, and health care service use/costs (pharmacy, outpatient, 
inpatient, and total) between patients with CLBP and patients without a CLBP diagnosis in a cost 
of illness study of 101 294 patients from a life insurance database. They found that patients with 
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the CLBP diagnosis had a significantly higher level of health resource utilisation and health care 
costs.  
Back problems were ranked sixth of the 15 most costly conditions in America, with national costs 
of $12.2 billion192. In the same study, back problems were ranked fourth of the 20 most costly 
health conditions for employers.  
1.7.2 Cost-effectiveness studies 
The following definitions are from the textbook of Drummond et al193: 
1. Economic evaluation always involves a comparative analysis of alternative causes of 
action.  
2. Analyses, in which costs are related to a single, common effect that may differ in 
magnitude between alternative treatment options, are usually referred to as cost-
effectiveness analyses (CEAs). 
The rationale behind CEAs is that the result of such analyses can act as a source of information 
for decision makers194. Two quantities are typically assessed: The additional costs of a new 
treatment compared with the existing alternative (or “standard treatment”) and the additional 
health benefits 195. Mean costs and mean effect for each treatment group are obtained  and the 
difference in costs between the “new” and standard treatment are divided by the difference in 
effects to present what is called the Incremental Cost Effectiveness Ratio or ICER194,196: 
ICER = Ct – Cc /Et – Ec = ȴC/ȴE = Costs pr unit of health gained 
The ICER reflects the cost per unit of health benefit obtained from switching from one 
intervention to another 196.  
Variation in the numerator (incremental cost) and denominator (incremental effect) introduces 
sampling uncertainty 196,197 . Claxton197 find it useful to distinguish between variability, 
heterogeneity and uncertainty in economical trials. While variability refers to the natural 
variation between patients in their response to treatment and the costs they incur, 
heterogeneity refers to differences between patients who have different characteristics. The 
uncertainty then refers to the fact that we can never know the true mean of costs and effects as 
it will vary from study population to study population.  
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The uncertainness of the ICER estimate can be presented in a cost-effectiveness plane 198 (fig 3). 
Here, the incremental effect is plotted on the X-axis and the incremental costs on the Y-axis. The 
slope of a ray from the origin to any cost-effect combination represents the cost-effectiveness 
ratio 194. In our study we also make use of Cost Effectiveness Acceptability Curves (CEAC) to 
graphically visualize sampling uncertainty in relation to a willingness to pay limit. Such curves are 
constructed by calculating the probability that the estimated cost-effectiveness ratio falls below 
specified values of willingness to pay 199. 
 
 
 
Figure 3. The cost-effectiveness plane. 
 
As an expression for the effectiveness (or health gained), the outcome scores of general HRQoL 
questionnaires can be stratified into different health states 200,201. Using different techniques 
(see later), a random sample of people from the normal population is asked to evaluate different 
health states202,203. Treatment benefit is thus expressed in a way that allows health states that 
are considered less preferable (0) to full health (1) to be given quantitative values. Because these 
quantitative values represent a valuation or preference of health states for the patients, they are 
called utility indexes (more utility for the patient with increasing value) or preference-based 
measures (some health states are preferred over others)204. When combined with a follow-up 
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period, health utility indexes are used to calculate QALYs194. Two of the most used indexes are 
the EQ-5D and the SF-6D203,205,206. Health economic studies that use QALYs as a measure of 
effectiveness are called cost-utility studies193,207,208. QALYs have the advantage of combining 
multiple dimensions of outcome (survival and quality of life) into a single measure that allows 
comparisons to be made across therapeutic areas and illnesses194. 
Various methods are used to measure health state preferences193,194,200,209. At least two 
techniques have been described 205,210: the Time Trade Off (TTO) and the Standard Gamble (SG) 
methods. In the TTO method, the subject is offered two alternatives: either to live with a chronic 
disease/health state for a certain time t followed by death or to be healthy for a time x < t. Time 
x is then varied until the subject is indifferent between the two alternatives193. In the Standard 
Gamble (SG) method210, the subject is offered two alternatives: alternative one is to live with the 
chronic disease until death; alternative two is to either return to perfect health and live for an 
additional t years with a probability p or immediate death with a probability of 1-p. p is then 
varied until the subject is indifferent between the two alternatives193. While the TTO method 
was used to construct EQ-5D utilities, the SG method was used to construct the SF-6D utility 
index.203,205,206. 
1.7.3 Cost-effectiveness studies on the treatment of CLBP 
Rivero-Arias et al211 compared fusion surgery with an intensive programme of rehabilitation in 
patients with CLBP in a cost-utility study alongside a clinical randomised trial. They found that 
surgical stabilisation with fusion surgery might not be cost-effective. However, there was a 
question of selection bias in this study as patients were eligible if the clinician and patient were 
uncertain which of the study treatment strategies was best153.  
In 2004, Fritzell et al 212 reported that fusion was more expensive than non-specific rehabilitation 
(treatment as usual) after 2 years but that cost-effectiveness was dependent on the threshold of 
willingness to pay (WTP) set by the society. 
Fritzell213 also assessed the concept of TDR compared with instrumented lumbar fusion (FUS) in 
a cost-utility study alongside a randomised controlled trial. They found that TDR was significantly 
less costly from a healthcare perspective but, because of a non-difference in clinical outcome, 
the cost/QALY was not meaningful to calculate. In this study, it was not possible to state whether 
TDR or FUS was most cost effective after 2 years.  
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Schweikert et al concluded that the addition of cognitive-behavioural treatment to standard 
therapy compared with standard 3-week inpatient rehabilitation for patients with CLBP might be 
cost effective by reducing work days lost 214. This finding was later confirmed215. Skouen et al 
concluded that the light multi-disciplinary treatment model was a cost-effective treatment for 
men with CLBP, using a form of MDR similar to that used in the present study 216.  
In a RCT setting, Søgaard 217 et al compared simple behavioral extension of setting up group 
meetings for patients to a strict physiotherapeutic focus. They found that the behavioral model 
was cost effective over strict physiotherapy and that increasing frequency and guidance of a 
traditional physiotherapeutic regimen was unlikely to be cost-effective. Jensen et al 218 
compared brief intervention to multidisciplinary intervention in a recent cost-effectiveness 
study. They found that the brief intervention resulted in fewer sick leave weeks and was less 
expensive than the multidisciplinary intervention. The multidisciplinary intervention only 
outperformed the brief intervention in terms of costs in a subgroup of sick-listed employees who 
thought they were at risk of losing their job or had little influence on their work situation. 
Van der Roer219 compared intensive group training with physiotherapy as usual in a cost-
effectiveness study and found no difference in total costs and a non-significant difference in 
effect.  
Van der Roer et al186 also tried to assess the cost effectiveness of various interventions for LBP. 
Due to the heterogeneity of interventions, controls, and study populations, they concluded that 
more studies were needed before any conclusions could be made. In conclusion, the variable 
reporting quality of the few existing cost-utility studies of LBP makes direct comparison of the 
cost and effectiveness of different surgical and non-surgical treatment options difficult103,186,220-
222.  
 
1.8 Biomechanical aspects 
The intervertebral segment, acting as a unit, provides flexibility in movement by allowing 
bending, flexion, and torsion of the spinal column 18,42. Fujiwara et al 54,223 found increasing 
segmental motion with an increasing grade of degenerative changes up to a certain degree and a 
certain decrease with further degeneration. Segmental instability is frequently considered a 
cause of LBP43. It is thought that the excessive motion of the degenerative spine beyond normal 
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constraints can cause the compression or stretching of structures known to have nociceptors like 
ligaments, joint capsules, annular fibres, or end plates. This has partly been the rationale behind 
fusion surgery144,224.  
A few studies have assessed the range of motion (ROM) in segments with implanted disc 
prosthesis. Huang et al170 observed patients 7 to 10 years after implantation of the ProDisc II L 
prosthesis and found a segmental range of flexion-extension motion in the order of 3.5°. In 
contrast, Bertagnoli et al212 and Tropiano et al 225,226 observed a ROM in the order of 10° less 
than 2 years after implantation of the ProDisc II prosthesis. Reviewing studies with findings up to 
4 years after implantation of the SB Charité III prosthesis, de Kleuver et al155 reported an average 
ROM of 5°–12°. In a noticeable percentage of cases, the ROM deteriorated with time and some 
arthroplasties eventually resulted in fusion. Differences in cohort, the length of follow-up, 
prosthesis model, and surgical technique might be responsible for these discrepancies. In 
addition, measurement protocols differ among studies. As segmental motion is small, and the 
range of sagittal plane motion is given by the difference of two angles to be measured in flexion 
and extension, inferior measurement precision could have confounded the results of some past 
studies. 
In a review study early in the commercialised era of TDR (2002), de Kleuver155 noted that few 
studies evaluated the mobility of the prosthesis and those who did failed to describe the method 
used to measure the motion properties of the device. In a Cochrane review paper 10 years later 
of 40 randomised controlled studies on disc prosthesis, Jacobs et al177 noted that “The primary 
goal of prevention of adjacent level disease and facet joint degeneration by using total disc 
replacement, as noted by the manufacturers and distributors, was not properly assessed and not 
a research question at all”. Huang et al227 found a weak correlation between segmental ROM and 
clinical outcome.  
 
1.9 Outcome measures 
The ability to accurately assess severity and change in symptoms in a reliable and valid way is 
essential in clinical studies where outcomes reported by the patient are an issue228,229. Blazeby208 
defined PROs as “Outcomes that assess any aspect of a patient’s health that come directly from 
the patient without the interpretation of the patient’s responses by a physician or anyone else”. 
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The use of validated outcome measures or patient-related outcome measure (PROM) is 
essential224. A consensus for the taxonomy of measurement properties relevant for evaluating 
such health instruments has been reached by the COnsensus based Standards for the selection 
of health Measurement Instruments (COSMIN) group230-232.  
A variety of both generic and disease-specific instruments for measuring clinical outcome in low 
back patients exist233-236. Grotle229 reviewed 36 disease-specific outcome measures for back-
specific outcome questionnaires and found that only a few of them could be considered 
acceptably validated.  
The field of psychometrics is concerned with the construction and validation of measurement 
instruments that are used to measure clinical outcome237. Central concepts are Classical Test 
Theory (CTT) and Item Response Theory (IRT). CTT comprises a set of principles that seek to 
clarify how successful a questionnaire or instrument is in estimating clinical outcome238. IRT 
assumes that patients with a particular level of quality of life (or other traits) will have a certain 
probability of responding positively on questions (items) according to their level of ability (e.g., 
more or less pain)239. Central to IRT is whether an instrument constitutes a single composite 
scale, i.e., taps a single underlying construct. If a certain criterion is fulfilled then the 
questionnaire is said to be unidimensional; the underlying trait is measured along a continuous 
scale240. In our study of measurement properties of the ODI, EQ-5D, and SF-6D, we used both 
CTT and IRT. 
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2 AIMS  
 
The aim of this randomized controlled study was to provide an improved foundation for the 
choice of treatment for patients with degenerative disc disease and chronic low back pain. More 
specifically, we wished to find out whether surgery with total disc replacement or 
multidisciplinary rehabilitation would provide the best clinical results and health economical 
efficacy two year after treatment start. In addition, we wished to evaluate some outcome 
measures used in health economic analysis of patients with low back pain. 
 
2.1 Specific aims: 
x To assess patient related outcome after treatment with TDR compared to MDR.  
 
x To assess the cost-effectiveness of TDR compared to MDR. 
 
x To assess the biomechanical properties of intervertebral disc prosthesis and its relation 
to clinical outcome.  
 
x To assess the impact of using different utility measures for estimation of efficacy in cost 
utility studies. 
  
40 
 
  
41 
 
3 METHODS 
 
3.1 Design 
This was a multicenter study conducted at five university hospitals in Norway. The study was 
designed as a randomized controlled trial (RCT)241. The trial was designed to have 80% power to 
detect a significant difference of at least 10 points in change in the mean Oswestry disability 
index score between the intervention groups at two year follow-up 152. Baseline standard 
deviation was estimated at 18 242. Considering these assumptions and adding 25% for a 
multicenter study design and 30% for possible drop-outs, we estimated we required 180 
patients. We included patients with low back pain and degenerative discs in the period between 
April 2004 and May 2007. All patients were treated within three months after randomization. 
Patients were randomized in blocks with a website hosted by the medical faculty. Allocation was 
concealed for all people involved in the trial. A coordinating secretary not involved in the 
treatment could access randomization details on the internet. The patient and the treating unit 
were informed about the allocation shortly after randomization. At each center (the five 
university hospitals), patients were stratified on whether they had had previous surgery 
(microsurgical decompression) or not (before randomization). Independent observers collected 
and entered data. 
 
3.2 Participants 
Patients from all health regions in Norway were included. Participants were recruited from 
patients submitted to the five university clinics for low back pain and included or excluded 
according to certain exclusion and inclusion criteria. No supplemental recruitment attempts 
were done. Mean age (SD) was 41.1 (7.1) years in the surgery group and 40.8 (7.1) years in the 
rehabilitation group. There were 40 women (47%) in the surgery group and 51 (59%) in the 
rehabilitation group. Mean (SD) duration of back pain (months) was 76 (72) in the surgery group 
and 85 (74) in the rehabilitation group. Most baseline characteristics were similar in the two 
treatment groups. Low back pain score and SF-36 mental health subscores, however, were 
significantly worse in the rehabilitation group than in the surgery group. Of the 605 patients 
screened for eligibility, 173 were included in the study and treated between April 2004 and 
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September 2007 (86 with surgery and 87 with rehabilitation). The drop-out rate from inclusion 
to two year follow-up was 15% (n=13) in the surgical arm and 24% (n=21) in the rehabilitation 
arm. Five patients (6%) crossed over from rehabilitation to surgery, but none crossed from 
surgery to rehabilitation.  
In the health economic analysis, 144 of the 173 patients included in the clinical outcome study 
provided enough data on cost and resource use and were considered eligible for the health-
economic analysis; 68 of these patients were in the rehabilitation group and 74 were in the 
surgery group. 
In the DCRA study, 120 patients (74 in the prosthesis cohort, 46 in the intensive rehabilitation 
cohort) provided x-rays of acceptable quality and were included in the final analysis. The mean 
age was 42 (SD 7.35) years with 65 (54%) women, and the mean duration of back pain was 81 
(SD 77) months. 
In the methodological study comparing the utility indices, 133 out of 173 patients had 
completely filled out the ODI, the EQ-5D, and the SF-6D (SF-36) at baseline so values for each of 
the instruments could be calculated. At 2-year follow up, 113 patients had values for all three 
instruments, so change scores could be calculated. 
 
3.3 Treatment 
3.3.1 Surgery 
The Prodisc-L prosthesis (ProDisc II, Synthes Spine) is a semiconstrained type prosthesis (table 3). 
It is unconstrained in axial rotation and semi-constrained with respect to flexion, extension and 
lateral bending. It consists of 3 parts: A lower and an upper endplate of 
Co-Cr alloy with a keel and between these an insert of polyethylene  
(UHMWPE – ultra high molecular weight polyethylene) which is attached 
to the lower endplate 171. The endplates comes in large or medium size, 
the angle between them 6 or 11 degrees and  the height between them 
10, 12 or 14 mm. Access was made through a Pfannenstiel or a para-
median incision with a retroperitoneal approach243. Nearly whole of the 
diseased disc was removed and the ProDisc II prosthesis was placed using instruments from the 
Figure 4. The ProDisc II 
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manufacturer with the guide of a fluoroscope. The operation technique was standardized and 
the surgeons who performed the operation should have inserted at least 6 disc prostheses 
before operating on the patients in the study. Hospital stay postoperatively varied from 2 to 21 
days (mean 7 days) postoperatively. Routinely they got a sick leave for 6 weeks on departure 
from hospital. They were not allowed to receive any kind of physiotherapy training until the first 
control 6 weeks postoperatively.  
3.3.2 Multidisciplinary Rehabilitation 
This was an outpatient programme with emphasize on exercises and cognitive intervention. The 
model was similar to that used in the study of Brox et al 151,152. Before the study started three 
consensus conferences were held with physiotherapists and specialists in physical medicine and 
rehabilitation from the five study centers in order to standardize the treatment. The treatment 
was interdisciplinary and directed by a team of physiotherapists and specialists in physical 
medicine and rehabilitation. Patients were given exercises and education 5-6 hours a day 5 days 
a week for 3 weeks. In the exercise part, emphasis was put on general mobility and included 
water exercises, general strength work outs and endurance training outdoor and indoor. In the 
educational part lectures about basic physiology and anatomy of the back and pain physiology 
were given along with motivational lectures. In the motivational lectures it was stressed that 
taking part in physical activities was not dangerous and did not aggravate problems with low 
back pain. This message was later reinforced both during treatment and on follow up. Cognitive 
coping strategies were discussed with the patient individually or in groups. With local 
adjustments, services from other specialties like psychologists, nurses and social workers were 
also offered. As a part of the treatment plan patients were invited to a control at the outpatient 
clinic three, six and twelve months after the end of the programme.   
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3.4 Imaging 
In our study, inclusion criteria included several degenerative changes of the intervertebral disc 
visualized on MRI that were thought to have relation to the experience of low back pain 119,244,245. 
The MR series was evaluated by two independent observers 140,246,247. 
3.4.1 Disc height 
The midsagittal diameter of the intervertebral disc was measured in mm 109. Interobserver 
reliability was moderate to good (k = 0, 62 at L4/L5 and 0, 58 at L5/S1) 246. 
3.4.2 Modic changes (MC) 
The primary and secondary signal intensity changes in the vertebral bone marrow adjacent to 
the endplate were rated as: 0 = no changes, type I = hypointense T1 signal and hyperintense T2 
signal, type II = hyperintense T1 signal and iso- or slightly hyperintense T2 signal, and type III = 
hypointense T1 signal and hypointense T2 signal 120. 
The maximal craniocaudal (CC) extension of MC at each separate endplate were rated based on 
the Nordic Modic Consensus Group criteria: 0 = no signal changes, 1 = located to the endplate 
only (minimal or small dots), 2 = less than 25% of vertebral body height, 3 = 25 – 50% of 
vertebral body height, 4 = more than 50% of vertebral body height 248. Based on our data, the 
interobserver reliability was found to be moderate or good for type and extent (k = 0,55 – 0,77) 
246. 
3.4.3 Posterior HIZ 
The area of high-signal intensity in the posterior annulus fibrosus that is brighter than nucleus 
pulpous on T2-weighted images and is surrounded superiorly, inferiorly and anteriorly by the 
low-intensity (black) signal of the annulus fibrosus was rated as present or non-present 125. 
Interobserver reliability was found to be moderate, but better at L4/L5 than L5/S1 (k = 0,58 vs. 
0,46) 246. 
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3.4.4 Nucleus pulposus signal 
The signal was visually rated as bright (1), grey (2), dark (3) or black (4) on sagittal T2-weighted 
images, using cerebrospinal fluid as intensity reference 134. Interobserver reliability was 
moderate to good (k = 0, 69 at L4/L5 and 0, 58 at L5/S1) 246. 
 
3.5 DCRA method 
3.5.1 Measurement protocol 
When measuring the rotational and translational segmental motion as well as disc height and 
dorsoventral displacement of lumbar columna segments, the method of Distortion Compensated 
Roentgen Analysis (DCRA) compensates for distortion caused by axial rotation, lateral tilt and 
off-centre positioning of the spine 118,249,250. This permits to process radiographs taken in normal 
clinical settings. Knowledge of the exposure geometry is not required. All motion segments 
imaged on a lateral radiograph can be evaluated. Sagittal plane rotational motion is obtained in 
degrees. Dorsoventral displacement and translational motion, disc height and vertebral height 
are determined in relative units, i.e. divided by the individual, mean vertebral depth. This is done 
in order to compensate for variations in radiographic magnification and stature.  
Measurement errors for sagittal plane rotational motion amount to 1.0q - 2.3° and for 
translational motion to 1.6% - 3.4% of vertebral depth, in both cases the largest error occurring 
at L5/S1. Disc height, dorsoventral displacement and vertebral height are determined with errors 
in the order of 1.8%, 1.5% and 1.2% of mean vertebral depth, respectively. To perform DCRA, the 
contours of the vertebrae are mapped and digitised. Series of computer programs check 
geometric properties of the contours, objectively locate vertebral ‘corners’ and calculate the 
parameters.   
3.5.2 Data collection and analysis 
Sagittal plane motion of the segments TH12/L1 to L5/S1 is determined from the pre- and 
postoperative pairs of flexion-extension radiographs. In the operated segment, disc height (or 
postoperatively: height of the intervertebral space) and dorsoventral displacement is 
determined from the pre- and postoperative radiographs taken in extension. As disc height and 
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displacement (as defined here) both depend on the angle of lordosis, and in order to permit 
comparison with normal data, disc height and displacement are corrected to standard angles of 
lordosis. For the purpose of quality control, height of the cranial and caudal vertebrae of the 
operated segments, measured from the pre- and postoperative pairs of radiographs, are 
compared: For each vertebra the four height values determined pre- and postoperatively in 
extension and flexion should coincide within the limits of the measurement error. Rotational and 
translational motion as well as disc height and dorsoventral displacement are compared with 
previously determined normal data 118,249. As the magnitude of translational motion depends 
linearly on the magnitude of rotational motion, actual translational motion is also compared 
with that motion predicted for a normal subject under the individual magnitude of rotational 
motion. Thus, the comparison between actual and predicted translational motion is independent 
of the magnitude of rotational motion performed by the patient. For the segments instrumented 
with disc prostheses, the deviation of disc height and displacement from the norm is expressed 
in standard deviations S of the appertaining distribution in the normal population. This permits 
to pool disc height and displacement data from all patients studied.  
 
 
 
Figure 5. Parameters measured by DCRA 
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Table 4. Definition of DCRA parameters 
DCRA parameter Definition (figure 5) 
Mean vertebral depth Mean distances between corners 1 and 2 and corners 3 and 4 
Sagittal plane angle Angle between vertebral midplanes. The vertebral midplane is defined 
as the horizontal line that runs through the midpoints between the 
upper and lower corners of a vertebra (i.e. midway between corners 1 
and 3 and corners 2 and 4). 
Disc height The sum of the distances from the corners of the adjacent vertebrae 
(e.g. corner 2 of the caudal disc and corner 4 of the cranial disc) to the 
bisectrix between the midplanes. This sum is divided by the mean depth 
of the cranial vertebra in order to express the value in units of vertebral 
depth. In this study, the term “disc height” is used synonymously with 
“intervertebral space”. Disc height can be compared with age- gender 
appropriate data. As the given sagittal plane angle is typically different 
from the reference angle of the normative database. The deviation of 
the corrected height of the intervertebral space from the norm is then 
dependent of the sagittal plane angle adopted when the radiograph was 
taken. 
Posteroanterior 
(dorsoventral) 
displacement 
Distance between the centre points (geometric centre of corners 1 
through 4) of the vertebrae to the bisectrix, divided by the mean depth 
of the cranial vertebra. Displacement is counted as positive when the 
cranial vertebra is displaced in the anterior direction with respect to the 
caudal vertebra. Displacement can be compared with age- and gender 
appropriate normal data. As the given sagittal plane angle is typically 
different from the reference angle of the normative database, a 
correction is applied prior to the comparison. The correction depends 
linearly on the difference between the given sagittal plane angle and 
the corresponding reference angle of the norm. The deviation of the 
corrected displacement from the norm is then dependent of the sagittal 
plane angle adopted when the radiograph was taken. This holds for 
both mobile and fused segments. 
Sagittal plane range of 
motion 
The midplane angle during low back extension minus the midplane 
angle during low back flexion 
Sagittal plane 
translational motion 
The posterior displacement during low back extension minus the 
posteroanterior displacement during low back flexion 
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3.6 Instruments (Patient Related Outcomes) 
3.6.1 ODI 
As the primary outcome measure, we used the Oswestry Disability Index. The ODI is a back-
specific questionnaire 251,252. Patients rate physical disability in activities of daily living due to low 
back pain in 10 questions, each of which has verbal response alternatives. Ratings are summed 
to yield a score ranging from 0 (not disabled at all) to 100 (completely disabled). The ODI has 
been found to be a responsive and valid measure for patients with LBP 242,251,253. We used the 
Norwegian translation of the validated questionnaire (version 2.0)253. 
3.6.2 SF-36 
The Short Form 36 (SF36) is a generic health related quality of life questionnaire254. It measures 
quality of life along eight dimensions: Physical function, role physical, bodily pain, general health, 
vitality, social function, role emotional and mental health. Each dimension has 4-6 questions or 
items. Scores range from 0 to 100, higher scores corresponds to better health status. We used 
the Norwegian version of the SF-36v2. SF-36 are found to be a good measure of health status 
and patient function when compared to a disease specific instrument for low back pain 
patients236,255,256. 
3.6.3 SF-6D 
The SF-6D utility index is comprised of 11 items from the SF-36 254 that were revised into a six-
dimensional health state classification system. The six dimensions are physical functioning, role 
limitations, social functioning, pain, mental health, and vitality. It reflects a continuous outcome 
scored on a 0.29–1.00 scale, with 1.00 indicating full health 202. SF-6D health states were 
evaluated against a normal population using the Standard Gamble (SG) method. We used the 
United Kingdom (UK) tariff 202. The SF-6D was calculated based on the Norwegian SF-36 (version 
2) with the use of syntax files in SPSS 15(SPSS, New York, US).  
3.6.4 EQ-5D 
For the EQ-5D utility index, responses on a questionnaire with five dimensions, each comprised 
of three levels, are revised into an index with a range from -0.59 to 1, with 1.00 indicating full 
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health. The 243 possible health states on the EQ-5D are evaluated against a normal population 
using the time trade off method (TTO)205 257. We used the Norwegian version of the EQ-5D and 
syntax files obtained from the EQ-5D society using the UK tariff to calculate the index.  
3.6.5 Other instruments 
For psychological variables we included emotional distress (Hopkins symptom check list (HSCL-
25), scores range from 1 to 4, with lower scores indicating less severe symptoms) and the fear 
avoidance belief questionnaire (FABQ) for work and physical activity (scores range from 0 to 42 
(work) and from 0 to 24 (physical), with lower scores indicating less severe symptoms)258,259. Self-
efficacy beliefs for pain were registered by a subscale of the arthritis self-efficacy scale (scores 
range from 1 to 10 and are summarized and divided by 5; lower scores indicate uncertainty in 
managing the pain)260.   
At the two year follow up control, two independent observers blinded to treatment evaluated 
patients using the back performance scale which consists of five tests with a score ranging from 
0 to 15, worst possible261  and the Prolo scale which consists of functional and economic parts, 
summed to a worst score of 2 and a best score of 10262,263. 
We also recorded satisfaction with the result of the treatment on a seven point Likert scale, and 
satisfaction with care on a five point Likert scale 235.  
The visual analog scale (VAS) were also used 264. It is one of the most used outcome instruments 
to measure pain 256. Patients were asked to rate the intensity of low back pain on a visual 
analogue scale, ranging from 0 (no pain) to 100 (worst pain imaginable). 
 
3.7 Health economic analysis 
We performed a full health economic evaluation using a cost-utility analysis 193,194,198. 
3.7.1 Treatment effects and health utilities 
The EQ-5D utility index 265 was used in the main analysis and the SF-6D utility index 266 was used 
for comparison 267. Both costs and effects were measured at baseline; 6 weeks (not SF-6D); and 
3, 6, 12, and 24 months post-treatment. Combining utility indexes and time, the quality-adjusted 
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life years gained (QALYs) were estimated as area-under-the-curve (AUC) using the trapezoidal 
method 194,268. 
3.7.2 Costs and resource use  
All relevant costs were identified, measured, and valued. Resource use was assessed, and the 
analyses were performed from a societal perspective, including index treatment, other hospital 
care, primary care, patients' private costs, and costs due to loss of production both for the 
patient and their relatives. The Norwegian krone (NOK), with 2006 as a base year was used, and 
costs were inflation-adjusted into 2012 prices and converted into Euros using the rate 1 €2012 = 
6.7 NOK2006. Actual costs were assigned to patients regardless of their randomized group, so 
patients who were randomized to receive MDR but crossed over and received operation after 
having had MDR were assigned costs for both treatments.  
All relevant costs and resources were identified, measured, and valued as follows: 
1. Index treatment. For TDR, the resource use multiplied by unit costs, and incorporating spare 
capacity when appropriate, summarized the cost for each Index treatment. Cost components 
included were: prosthesis, operation room time, wake-up services, post-operative stay in 
hospital, and post-operative x-ray.  
For MDR, we used a top-down approach, i.e., the total cost of a spine clinic was estimated, and 
then how much of the clinic's costs were associated with MDR was determined 269. A 
consequence of this approach is that the costs are the same for all patients. Spare capacity was 
included. A premium of 12% was added to common costs based on data from previous estimates 
of the cost weights for the Norwegian DRG system (ISF) 270.  
2. Hospital costs during follow-up. The number of planned and unplanned re-admissions, 
including outpatient visits and re-operations were registered in electronic patient administrative 
systems. Patients who underwent surgery received one mandatory consultation with an X-ray 6 
weeks after surgery. Patients in the MDR group were offered four follow-up consultations at 6 
weeks and 3, 6, and 12 months, and costs were assigned if accepted.  
3. Primary care costs during follow-up. Unplanned visits to general practitioners, 
physiotherapists, or other practitioners in the public health service were recorded in a cost diary 
kept by the patient as described in a previous cost-effectiveness study 212. 
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4. Patients' private resource use. The use of medication (both prescribed and over-the-counter), 
contact with practitioners outside the public health service, and other costs were reported by 
the patient in a cost diary. Costs for relatives were included. 
5. Loss of production. The human capital approach was used to estimate the costs related to 
days each patient spent out of work due to low back pain. Costs related to production losses 
were calculated as the number of days out of work multiplied by the average wage adjusted for 
part-time sick leave. Income before taxes was used for patients and after taxes for relatives 
when calculating costs related to work loss 271. 
 
3.8 Psychometric evaluation of outcome instruments 
We used criteria from the COSMIN checklist272 for assessing five central measurement properties 
when comparing the EQ-5D, the SF-6D and the Oswestry Disability Index: 
1. Measurement error concerns the systematic and random error of a patient`s score that is not 
attributed to true changes in the construct to be measured 231. 
2. Structural validity concerns the degree to which the scores of an instrument are an adequate 
reflection of the dimensionality of the construct to be measured 272. 
3. Criterion validity concerns the degree to which the scores of an instrument are an adequate 
reflection of a “gold standard” when this is present 272. 
4. Responsiveness is defined as the ability of an instrument to detect change over time in the 
construct to be measured 272. 
5. Interpretability concerns the qualitative meaning of quantitative scores or change in scores. A 
core question is: “What is the smallest change in score in the construct to be measured which 
patients consider important?” This is expressed as the Minimal Important Change (MIC) value 
272. 
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3.9 Statistical methods 
3.9.1 Study 1 
The main statistical analysis was in the intention to treat population at one and two year follow-
up. According to our protocol the analysis was performed with the assumption that patients who 
dropped out had no improvement after drop-out (last value carried forward). We also 
determined if different centres had different outcomes. We used ʖ2 test or Fisher’s exact test to 
analyze categorical variables and independent two sided t test or analysis of variance to analyze 
continuous variables. A significance level of 5% was used throughout. We did not adjust for 
significantly different baseline scores. We conducted a per protocol analysis for the primary 
outcome variable (score on Oswestry Disability Index). Consistent with criteria from the Food 
and Drug Administration, we considered an individual change in score of at least 15 points from 
baseline to two year follow-up as a minimal important change. A deterioration of 6 points in the 
score was considered a “change for the worse”274. We calculated the number needed to treat 
with confidence intervals275. A mixed model analysis was used to evaluate the effect of each 
efficacy variable over time and between groups. In the mixed model patients were not excluded 
from the analysis of an efficacy variable if the variable was missing at some, but not all, time 
points after baseline. In the additional analysis (categorical or ordinal data at two year follow 
up), missing data were not replaced. Significantly different baseline scores were not adjusted for 
in the longitudinal model. Each outcome variable was adjusted for the baseline values of the 
variable. 
3.9.2 Study 2 
Time-weighted averages of the preference scores that were measured at the beginning and end 
of each measurement period were used to calculate QALYs from the EQ-5D and SF-6D 
utilities.194 The accumulated QALYs for TDR and multidisciplinary rehabilitation over 24 months 
were calculated for the following periods: baseline to 6 weeks (not SF-6D), 6 weeks to 3 months 
3 to 6 months, 6 to 12 months, and 12 to 24 months213. 
An incremental cost-effectiveness analysis of the index treatment was carried out. Cost 
effectiveness was calculated as the difference between the costs of the surgery group and the 
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rehabilitation group divided by the difference in QALYs gained between the two groups. The 
results are presented as the incremental cost-effectiveness ratio (ICER). 
In order to derive a 95% confidence interval (CI) for the ICER, we used a nonparametric 
bootstrap method using 10,000 replications 85. The bootstrap replications were plotted in a cost-
effectiveness plane to illustrate the uncertainty of the ICER estimate 276. The concept of net 
monetary benefit was used to construct a cost-effectiveness acceptability curve (CEAC).277 CEAC 
shows the probability that surgery is cost effective at 2 years in terms of the desired QALY.277 
Patients who dropped out of this study during the first 6 months of follow-up were removed 
from further analysis because it was believed that information regarding resource use and utility 
values would be too scarce for further analysis. Patients who crossed over from one treatment 
group to the other were analyzed according to the intention to treat principle: After cross-over, 
further resource use and utility values were analyzed according to the group the patient was 
randomly assigned to at baseline. 
In this study, 13% of the resource use items on follow-up and 8.3% of the utility scores were 
missing between baseline and 24 months. Multiple imputations were used to address these 
missing data.278-281 Each missing value was replaced with m plausible values, where m is the 
number of imputations performed. The missing values were replaced using a multiple linear 
regression model. The covariates included the intervention group, age, and sex. This imputation 
method was used to determine both the costs of the resources and the utility scores used to 
produce m = 5 data sets. Arithmetic means and 95% CIs are presented for the costs and QALYs of 
each trial group and the average of the means of the five datasets.  
The Student t test and corresponding 95% CIs were used to analyze differences in cost and 
utility. The Chi-square test was used to analyze differences in the times required to return to 
work. Two-sided p values < 0.05 were regarded as significant.  
3.9.3 Study 3 
The independent t-test was used to examine the differences in ROM, disc height, and alignment 
between the disc prosthesis cohort and the non-operated cohort. The independent t-test was 
also used for comparing inter-individual changes in the prosthesis group. When comparing intra-
individual changes from the start of the study to the two-year follow up, a paired t-test was used 
in the non-operated segments of the prosthesis group and in all segments of the intensive 
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rehabilitation group. The dependent t-test was used for intra-individual changes in operated 
segments. Spearman’s rank correlation coefficient was used to examine the association between 
disc height and segmental motion against the clinical postoperative variables ODI, EQ-5D, VAS, 
and the PF of SF-36. In patients with disc prostheses at two levels, segmental range of motion 
and disc heights were averaged when assessing the correlation to clinical outcome. Therefore, 
one and two level disc prosthesis patients were analysed as one cohort 227.  
3.9.4 Study 4 
A combination of statistical methods is generally recommended for interpreting changes of 
patient related outcomes 282,283.  
1. Measurement error 
We used the standard error of measurement (SEM) to express instrument imprecision 235,284-286. 
The advantage of using SEM is that it is considered to be an attribute of the measure and not a 
characteristic of the sample itself287. The SEM value could be calculated from a test-retest study 
or in a group of stable patients. The SEM in this study was calculated as:  
21
2w t
S SEM d
n
  ¦
 
where sw is the within-subject standard deviation, d is the difference between two observations 
in patients i who reported “unchanged” on a four-point scale between 3 and 6 months follow up 
and n is the number of subjects288. The sw statistics is also called the SEMconsistency289. 
 
The lowest change that exceeds measurement error and noise at a 95% confidence level is 
defined as: 
SEMSEMMDC *77.2*2*96.195    
 
Here, the *  is introduced because there are two measurements for each patient. The minimum 
detectable change (MDC) at a 95% confidence level, is denoted MDC95290. With a scale value 
2
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шMDC95, we can be 95% certain that a change in the measured underlying construct has really 
occurred274.  
To assess the agreement between EQ-5D and SF-6D, a Bland Altman plot was constructed. 291. 
The average EQ-5D and SF-6D change score values were plotted against the mean difference in 
change score values of both instruments. Limits of Agreement (LoA) based on a +/- 
196*SDdifference  interval for the differences were also constructed. 
2. Structural validity 
Both EQ-5D and SF-6D are constructed to measure the dimension of general health related 
quality of life (HRQoL) alongside a continuous scale (from low to high). Using Item Response 
Theory (IRT), the unidimensionality of the two utility indexes was tested. The category ordering 
of the questionnaire items (the probability of moving from an easier to a harder accomplished 
category of item answers in parallel with being increasingly disabled) was also tested.  
We employed the unrestricted (Partial-Credit) polytomous model of the Rasch model (for 
general information about fit to the Rasch model, see appendix A) and the test proposed by 
Smith to reveal unidimensionality 292. The SF-6D and EQ-5D were tested for unidimensionality in 
a principal component analysis (PCA) 293. We performed a test equating procedure with baseline 
values from the SF-6D and the EQ-5D. The response of each patient to a question was tested 
against what was predicted by the Rasch model. Deviation from the model is expressed in 
residuals. Independent t-tests were used to test if the magnitude of the residuals represents a 
significant deviation. The CI calculated for this was 95%. We carried out a binominal test for the 
proportion of t-tests outside the range of -1.96–1.96. 
3. Criterion validity 
In this analysis we compared the scores of the EQ-5D and SF-6D to the disease specific 
instrument ODI. The rationale was that the ODI has been found to be a responsive and valid 
measure for patients with LBP 242,251,253and that an improvement assessed by the ODI should be 
correlated with an improvement assessed by the two utility indexes.  
Spearman rank correlation coefficient (r) with 1000 bootstrap replications of the baseline scores 
was calculated to assess the correlation between the scores of the EQ-5D and ODI and SF-6D and 
ODI. 
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4. Responsiveness 
Responsiveness was assessed by using the ODI and the seven-point global scores at 2-year 
follow-up as “gold standard”. First, we calculated the Spearman rank correlation coefficient (r) 
with 1000 bootstrap replications for the correlation between change scores from baseline to 2 
year FU for the EQ-5D, SF-6D and ODI. Second, we analyzed the area under the Receiver 
Operator Curve (ROC) for the change scores of the EQ-5D, SF-6D and ODI by using a 
dichotomization of the patient global scores as follows: Categories 1 to 3 was considered 
“improved” and categories 4 to 7 were “non-improved”. Sensitivity was defined as the 
proportion of patients who were correctly classified as “improved” and specificity was defined as 
the proportion of patients who were correctly classified as “non-improved”. A receiver operating 
characteristic (ROC) curve was then calculated by plotting every possible change score from 
baseline to 2 year FU for EQ-5D, SF-6D and ODI using the global score as an anchor294,295. The 
area under the ROC curve (AUC) was then calculated. This value corresponds to the possibility of 
correctly diagnosing a patient as having improved when this is really the case295 and reflects how 
responsive the instruments are to detect a change in the underlying construct.  
5. Interpretability 
Interpretability was calculated based on the sensitivity and specificity results from the ROC 
analysis described above. The cut-off value for differentiating between patients with or without 
improvement at optimum sensitivity and specificity was determined using ROC analysis 295. This 
corresponds to the upper left point on the ROC curve and it can be interpreted as the point or 
value that yields the lowest overall misclassification 284,296.  
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4 RESULTS 
Paper I: Surgery with disc prosthesis versus rehabilitation in patients with low back pain and 
degenerative disc: two year follow-up of randomized study 
In the planned analysis, the mean change from baseline to two-year follow-up was 20.8 ODI 
points (95% CI, 16.4 to 25.2) in the surgery group and 12.4 points (95% CI, 8.5 to 16.3) in the 
rehabilitation group. The mean treatment effect (between-group difference) at two-year follow-
up was 8.4 ODI points (95% CI, 3.6 to 13.2). In the mixed model analysis (unplanned analysis 
according to the original protocol), ODI improved significantly more in the surgical group than 
the rehabilitation group at all time points. The mean change from baseline to two-year follow-up 
was 22.5 (95% CI 18.5 to 26.4) in the surgery group and 15.6 (95% CI, 11.7 to 19.5) in the 
rehabilitation group. The mean treatment effect (between-group difference) at two year follow-
up was 6.9 (95% CI, 2.1 to 11.7). 70% (n=51) of patients in the surgical group and 47% (n= 31) in 
the rehabilitation group had an improvement in ODI of at least 15 points (p< 0.006) in the 
unplanned analysis. The number needed to treat was 4.4 (95% CI, 2.6 to 14.5) (intention to 
treat). 
 
Paper II: Cost-effectiveness of total disc replacement vs. multidisciplinary rehabilitation in 
patients with chronic low back pain – a Norwegian multicenter RCT 
The mean QALYs gained (SD) using EQ-5D was 1.29 (0.53) in the TDR group and 0.95 (0.52) in the 
MDR group, a significant difference of 0.34 (95% CI, 0.18 to 0.50). The mean total cost per 
patient (SD) in the TDR group was €87,622 (58,351) compared with €74,116 (58,237) in the MDR 
group, which was not significantly different (95% CI: -4,041 to 31,755). The Incremental Cost 
Effectiveness Ratio (ICER) for the TDR procedure varied from €39,748/QALY (95% CI: €15990 to 
€65 645) using EQ-5D (TDR cost- effective) to €128,328/QALY (95% CI: €51 329 to €219 907) 
using SF-6D (TDR not cost-effective). Using per-protocol instead of ITT indicated that TDR was 
not cost-effective, irrespective of the use of EQ-5D or SF-6D. Not using multiple imputations for 
missing data resulted in a considerable loss of observations and higher ICER, rendering TDR not 
cost - effective. 
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Paper III: Segmental mobility, disc height and patient-reported outcomes after surgery for 
degenerative disc disease: a prospective randomized trial comparing disc replacement and 
multidisciplinary rehabilitation 
No significant change in movement in the sagittal plane from baseline (pre-surgery) to two years 
(post-surgery) was found in segments with TDR. At the L4/L5 segment, a significant difference of 
2,88° (p = 0.041, 95%CI: 0.11° to 5.25°) was found  between the two treatment groups at two 
year follow up with greater mobility in the TDR group. At the L5/S1 segment, a non-significant 
difference of 1.64° (p = 0.077, 95%CI: -0.18° to 3.47°) was found. It remained the same or 
increased slightly (significant at the L4/L5 level only) in untreated segments in the TDR group. 
The disc height was significantly increased in the TDR group compared to the MDR group. There 
was no correlation between segmental movement or disc height and patient-reported outcomes 
in either group two years after treatment. 
 
Paper IV: Comparison of the SF-6D, the EQ-5D, and the Oswestry Disability Index in patients 
with chronic low back pain and degenerative disc disease 
The SF-6D had better similarity with the disease-specific instrument (ODI) regarding sensitivity, 
specificity, and responsiveness. Measurement error was lower for the SF-6D (0.056) compared 
to the EQ-5D (0.155). The minimal important change score value was 0.031 for SF-6D and 0.173 
for EQ-5D. The minimal detectable change score value at a 95% confidence level was 0.157 for 
SF-6D and 0.429 for EQ-5D. The difference in mean change score values (SD) between them was 
0.23 (0.29) exceeding the minimal important change score values of both measures.  Analysis of 
psychometric properties indicated that the indexes are unidimensional when considered 
separately, but that they do not exactly measure the same underlying construct.  
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5 DISCUSSION 
 
The principal findings from our study were: 
x A statistical significant difference in the main outcome variable (ODI)   in favor of disc 
prosthesis surgery when compared to non-surgical treatment was found. 
 
x Total disc replacement was cost-effective compared to multidisciplinary rehabilitation 
over two years. However, this result was dependent on the choice of clinical outcome 
measure for effectiveness (utility index). 
 
x No significant difference in range of segmental motion from pre- treatment to two year 
post-treatment was found in segments with prosthesis. No correlation between 
segmental movement and clinical outcome was found in either treatment group.  
 
x The difference in important measurement properties between EQ - 5D and SF - 6D, two 
of the most used patient related outcome variables in cost-effectiveness studies, was too 
large to consider them interchangeable.  
 
A general discussion about some aspects of the trial design is given before discussing the main 
findings in the trial. 
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5.1 Randomized controlled Trials and bias 
By randomly allocating patients to two or more treatments, the goal in randomized controlled 
trials is to eliminate bias 208,241,297. Jadad 241 defines bias as “…any factor or process that tends to 
deviate results or conclusions of a trial systematically away from the truth”. Several possibilities 
of bias exists 241. 
5.1.1  Selection bias 
Selection bias occurs when the way in which individuals are selected for a trial or the way in 
which the interventions are administered after people are accepted into the study affects the 
outcomes 241. 
Prior to randomization, patients in our study were interviewed and received information about 
the treatment options by both a physical internist and a surgeon. In that way, we ensured a 
balanced information process and that all patients were provided with the best available 
information concerning the treatment options. Participants found eligible for the study 
according to exclusion and inclusion criteria were then randomized in blocks of four at each of 
the study centers (university hospitals) with the help of a website hosted centrally by the 
medical faculty of the University Hospital of Trondheim, St Olav. This randomization process 
ensured that treatment group allocation could not be influenced by the investigators or the 
study participants.  
5.1.2  Ascertainment bias. 
Ascertainment bias occurs when the results or conclusions of a trial are systematically distorted 
by knowledge of which intervention each participant is receiving241,298. It can be introduced by 
the person administering the interventions, the participants, the investigators analyzing and 
assessing the outcomes and by people that write the describing report from the trial 241.  
Because of the nature of this trial, it was not possible to keep participants or personnel involved 
in the treatment unaware of the intervention identity after randomization had taken place.  
However, independent observers collected and entered data. In addition, two independent 
observers blinded to treatment 299 evaluated patients at the final two year follow up 
consultation. Patients were informed before this session not to reveal the treatment received 
and had a tape placed on their abdominal wall to hide scarring from the operation.   
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Patients may have had expectations about which treatment they could be allocated to. This in 
turn could influence on their motivation for treatment and the self-reporting of outcome after 
treatment. For example, one of the inclusion criteria was that patients should have had 
structured physical rehabilitation therapy with the duration of at least one year before attending 
the study. Patients randomized to the MDR could have felt that “this is more of the same” and 
because of that have lost their motivation. This could have influenced their answers when 
evaluated on the follow up controls. 
5.1.3 Bias introduced by inappropriate handling of withdrawals, drop outs and protocol 
violations.  
This type of bias could occur for example if patients that do not benefit from the treatment 
withdraw more often than those who stay in the study 241. To prevent this, we performed an 
Intention To Treat analysis with last value carried forward for patients who dropped out. This 
ensures that treatment groups are equal apart from random variations and at the same time, it 
allows for non-compliance and deviations from treatment approach as it would appear in 
routine practice outside a trial setting 300.  
It could be argued that patients who withdrew after randomization or dropped out during or 
after treatment had a superior or inferior outcome. In order to assess this, we sent a 
questionnaire to such patients. The nine patients who withdrew after surgery experienced a 
reduction in Oswestry score of 30.2 (SD 4.5) points. The six who withdrew after rehabilitation 
had a reduction of 11.8 (SD 3.0), and the 11 patients who withdrew without treatment had no 
change (1.0 (SD 4.5) points).This might support the assumption of no improvement in outcome 
after drop-out, justifying use of the last value carried forward analysis. 
 
5.2 Interpretation of main findings 
5.2.1 Surgery with disc prosthesis versus rehabilitation 
MDR 
The MDR used in this study was published in 2003 and 2006. It was a single center study and the 
multicenter intervention in the present study may differ slightly because it involves several 
centers with different treatment cultures. The mean ODI was reduced by 29% (12.4 points) in 
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the rehabilitation group of our study (ITT analysis). Two former single center studies have used a 
form of MDR similar to the one used in our study: Brox152,301 et al found an analogue reduction of 
29% (12.0 points) at one year follow up while Fairbank153 et al found a smaller reduction of 19% 
(8.7 points) at two year follow up.  
Such comprehensive regimens like the MDR in our study have not been well compared with 
more simple interventions like the brief intervention described by Indahl in the trial in the -90-
ties 302,303 and by Storheim et al in 2003 304,305. In the latter study the authors found no effect on 
return to work, but for most other variables a simple cognitive intervention (1-2 consultations) 
was better or as good as a more comprehensive group exercise program.  In our study, there was 
no difference between treatment groups in return to work after two years and the “net back to 
work”( subtracting patients who went back to work from patients who stopped working150) was 
31% (n=21) in the surgical group and 23% (n=15) in the rehabilitation group (P=0.31). 
 
TDR 
Previous studies have reported on the effectiveness and safeness of TDR surgery compared to 
fusion surgery306-313.  Due to different prosthesis designs and different outcome measures, it is 
not straight forward to compare these studies to our study. In addition, many of these studies 
has been assessed as of low quality either because of high risk of bias or conflict of interest177,314. 
In a Cochrane study, Jacobs315 et al looked at five studies with 1301 patients comparing TDR (865 
patients) to fusion surgery (436 patients). They conclude that although surgery with TDR 
compared to fusion surgery showed a statistical significant improvement in favor of TDR, the 
differences on the primary outcome parameters, including their 95% CIs, were small and did not 
exceed pre-defined clinical relevance. This was confirmed in a meta study by Eerenbemt314 et al 
which looked at 116 studies including prospective cohort studies, prospective controlled studies, 
cost-efficacy studies and studies reporting complication rates. 
 In a study including 7172 TDR procedures and 62 731 anterior fusion procedures, Kurtz316 et al 
found that the revision burden for TDR (11,2%) was significantly higher than fusion surgery 
(5,8%). Furthermore, the revision rate of TDR fell within the revision burden range of hip and 
knee replacement, which are generally considered successful and cost-effective procedures. In 
our study, there was a complication rate of 8% resulting in impairment at two year follow-up and 
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a revision rate of 6% including a patient that lost a leg as a direct consequence of revision 
surgery. This revision rate was within acceptable limit compared to other reports. However, it 
must be taken into account that we (similar to the aforementioned studies comparing TDR to 
fusion surgery) were not able to show a clearly clinical significant difference in ODI score at the 
two year follow up between treatment groups.  
Shear stress forces cause wear particles from the polyethylene inlay of the prosthesis to 
accumulate317-319.  Punt317 et al showed that the wear and tear of the polyethylene in TDR is 
compatible with total hip or total knee replacement. These particles cause an inflammatory 
response in the periprosthetic tissue and there is evidence of increasing wear with implantation 
time and a potential for osteolysis in the spine319,320.  Potential long-term revision rate with 
adhering complication rate on revisions needs to be considered 321. Several authors therefore 
recommend regular long-term follow-up for patients undergoing TDR318,319.  The need for longer 
follow up in the prosthesis group and the expenditure of this should therefore be taken into 
consideration when assessing and comparing clinical and health economic consequences of 
choosing disc prosthesis surgery. 
Serious consequences of vascular injury in anterior lumbar surgery seldom occur322 but could 
nevertheless be critical323 and should be accounted for when comparing treatment methods.  
The risk of vascular injury is greater during revision than primary procedures176. 
 
ODI 
The rationale for choosing ODI as the primary outcome variable was that it has been found to be 
a responsive and valid measure for patients with LBP 242,251,253. The ODI is by far the most used 
and validated disease specific instrument for patients with chronic low back pain 242. The validity 
and reliability of the Norwegian translation of the Oswestry Disability index was documented by 
Grotle et al 253. Even small changes can be detected with this instrument 256,324-326. The high 
responsiveness of ODI was confirmed in study IV were the area under the ROC curve, the 
possibility of correctly discriminating between “improved” or “non-improved” patients with a 
95% CI was 94% (87.5–97.6). The effect size of ODI in our study was quite similar to values 
reported in other studies of patients with low back pain 150-153 
Mean difference in improvement in Oswestry Disability Index after 24 months in the Cochrane 
study of Jacobs et al315 comparing TDR to fusion surgery was 4.27 (95%CI 1.85 to 6.88) well 
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below the pre specified clinical significant score value308 of the difference suggesting that there is 
no clinical relevant differences between total disc replacement and fusion techniques. While 
statistically significant effects are those that occur beyond some level of chance, clinical 
significance refers to the benefits derived from treatments, its impact upon the patient and its 
implication for clinical management of the patient 327,328. To assess the clinically significance in 
our study we used the concept of Minimally Important Change (MIC) in study IV 289. The MIC 
value was defined as the smallest change in ODI score from baseline to two year follow-up which 
patients considered important 237,289. The power analysis of study 1 was based on detecting a 
clinical significant difference between groups of 10 ODI points 151,152. Unfortunately, there is no 
agreement on the clinically important difference between two treatment groups so the value of 
10 ODI points in our study was a somewhat arbitrarily chosen limit. As an alternative, in study I, 
we assessed the proportion of patients that on an individually basis achieved a clinically 
meaningful improvement using a value of 15 ODI points 308,329. Using this value, 70% of the 
patients in the surgical group and 47% in the rehabilitation group achieved this clinical important 
difference.  However, it is generally recommended to calculate the MIC value specific to each 
study which we did in study IV 330,331. The MIC value for the ODI on an individually basis found in 
study IV was 12,88 (sensitivity 88%, specificity 85%), which was almost exactly the same value 
found in a study by Copay296 et al. Using this value, the numbers increased to 75% (n= 55) in the 
surgery group and 57% (n=37) in the rehabilitation group. The minimal detectable change score 
value at a 95% confidence level (MDC95, the limit for changes in score value that occur beyond 
measurement error or “noise” with a probability of 95%) calculated in study IV was 11.75 points 
for ODI. The number of patients in study I that experienced a change in ODI beyond this value 
(intention to treat) was 77% (n= 56) in the surgery group and 61% (n= 40) in the rehab group. 
Although recommended, these parameters (MIC and MDC95) are not usually presented in clinical 
studies with the ODI as an outcome variable but we think this is strength of the study because it 
gives a more precise estimate of the effect after treatment. 
The clinically important change score value of 12.88 ODI points found in study IV could be 
further compared to results from study I. In the primary (planned) analysis of the change in ODI 
score from baseline to two years follow-up, there was an improvement of 20.8 (95% CI 16.4 to 
25.2) in the surgery group and 12.4 (95% CI 8.5 to 16.3) in the rehabilitation group. In the mixed 
model analysis (intention to treat, unplanned analysis according to the protocol) the numbers 
were 22,5 (95%CI 16,4 to 25,2) for surgery and 15,6 (95%CI 11,7 to 19,5) in the rehabilitation 
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group. The method of last value carried forward was used in the first study in case of drop out 
with the assumption that patients who dropped out had no improvement after leaving the 
study. In the mixed model analysis, patients were not excluded from the analysis of an efficacy 
variable if the variable was missing at some, but not all, time points after baseline. The 
interpretation of this is that patients in the surgery group had a clinical important change in ODI 
score regardless of analysis method used while this was true for the patients in the rehabilitation 
group only when missing values were adjusted for. 
In conclusion, revision surgery after TDR surgery is complicated and potentially more dangerous 
than revision after fusion surgery. The need for longer follow-up because of wear and tear of the 
polyethylene inlay is recommended indicating increased resource use in this group. Surgery with 
TDR do not show a clearly clinically significant difference in improvement compared to fusion 
surgery in most studies. This is also the case when comparing TDR to MDR in our study.  
Finally, we based our study inclusion criteria on an anticipated causal relationship between 
clinical presentation of low back pain and morphological changes of the intervertebral disc on 
MRI scans. This correlation has not yet been fully established332. In a separate study we found 
that the combined MRI findings from our inclusion criteria were not related to the degree of 
disability or the intensity of LBP 247. Other contributing causes of low back pain should also be 
considered. 
5.2.2 Cost-effectiveness of total disc replacement 
As mentioned by Drummond et al, it is useful to contrast two different activities in health care 
evaluation: Measurement and decision analysis 193.  
We present results of a cost-utility analysis (measurement) based on a single randomized 
controlled trial as opposed to a modeled (decision) analysis. The latter would have permitted us 
to extend the follow up period beyond two years and to include more precise estimates of rare 
events. Also with a modeling approach, other relevant treatment options (e.g. different kinds of 
non-surgical treatment or no treatment) could be compared to TDR 193,194. A modeling approach 
may be a better tool to inform decision makers and perhaps make a better fundament for a 
decision analysis because the information is on a more general basis. 
Due to heterogeneity of the populations, interventions, and comparison groups, several authors 
of  review studies report that firm conclusions about the effectiveness of different non-surgical 
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treatment options are hard to draw 103,186. This heterogeneity in addition to variable reporting 
quality of the few existing cost utility studies of low back pain makes direct comparison of both 
effectiveness and cost of different non-surgical treatment options difficult 220. Thus, we cannot 
exclude that a much simpler intervention had been as effective and therefore influenced the 
cost-effectiveness (less costly, same effect). 
In our study, we found that cost per quality-adjusted life year (QALY) gained using TDR was 
€39,748/QALY (95% CI, €51 330 to €219 907) or approximately $53,627 (95% CI, $64 933, $278 
18) using EQ-5D. Tosteson et al compared surgery with nonoperative care for three common 
diagnoses: spinal stenosis (SPS), degenerative spondylolisthesis (DS), and intervertebral disc 
herniation (IDH) 333. Using EQ-5D as outcome measure for clinical efficacy, the costs per QALY 
gained decreased for SPS from $77,600 at 2 years to $59,400 (95% CI: $37,059, $125,162) at 4 
years, for DS from $115,600 to $64,300 per QALY (95% CI: $32,864, $83,117), and for IDH from 
$34,355 to $20,600 per QALY (95% CI: $4,539, $33,088). Although the indication for surgery is 
less controversial in the Tosteson study than ours, this illustrates how the cost-effectiveness for 
spine surgery may change in longer follow up studies perhaps because the improvement in 
quality of life is sustained while the cost pr QALY decreases with time. The results from the 
Tosteson study also show that our estimate of cost per QALY gained was in the same range as 
other common spinal surgery procedures when compared to non-operative treatment. We 
conclude in our study that longer follow-up is needed to assess how the cost-effectiveness of 
TDR will change. 
During follow-up, 13% of resource use data and 8.3% of utility scores were missing between 
baseline and 24 months. Although loss to follow-up could be regarded as being within 
acceptable limits 334, it is a limitation. Missing values and cross-overs were also within acceptable 
limits for a RCT, but are nevertheless problematic in all studies because it introduces additional 
uncertainty. Uncertainty in this cost-effectiveness study was handled formally in the sensitivity 
analysis. Three of the five sensitivity analyses performed changed the conclusions about cost-
effectiveness: Using SF-6D instead of EQ-5D, using per protocol instead of ITT, and not using 
multiple imputations. Five patients crossed over from MDR and underwent TDR but no one the 
other way. Surprisingly, the per-protocol analysis rendered surgery not cost-effective. The 
reason for this could be found in the 5 patients who crossed over. They were extremely costly 
compared to other patients and had a low gain in QALY’s. For this reason, the ICER was changed 
from € 39 772/QALY to € 86 712/QALY. Arguably, patients who do not follow their randomized 
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treatment are in one way or another different from the rest of their treatment group. These 
differences can be observed, for example if patients exhibit observable or unobservable 
comorbidities. For this reason, ITT analysis is considered the gold standard in health economic 
evaluations 335.  
Multiple imputation (MI) was used to avoid excluding patients with a few missing values and to 
avoid bias 278,279,281. The considerable loss of data not using MI could partly be explained by the 
nature of the outcome effect variable: EQ-5D is a scale variable comprised of 5 items. If an item 
is missing, the scale cannot be computed and the utility score for this patient will be missing. 
Standard regression analysis were used to provide estimates of the missing data conditional on 
complete variables in the analysis278,336. The complete variables included were intervention 
group, age, and sex. A “richer” model including more complete variables may have increased the 
precision of the imputated estimates. 
5.2.3 Biomechanical changes after total disc replacement 
No significant change in movement in the sagittal plane from baseline (pre-surgery) to two years 
(post-surgery) was found in segments with TDR. The clinical importance of the significant 
difference of 2,88° (p = 0.041, 95%CI: 0.11° to 5.25°) at the L4/L5 level between treatment 
groups are questionable.  At the L5/S1 level , segmental motion in spinal levels with implanted 
disc prosthesis did not differ significantly from same levels with a natural course. Mean range of 
motion (SD) in our study in segments with implanted prosthesis was 7.73 ° (6.46°) at the L4/L5 
level and 6.20° (4.82°) at the L5/S1 level. Ziegler et al report that ROM for ProDisc L© averaged 
7.7° two years after surgery but did not report the measurement method or measurement error 
306. Siepe et al reported a decrease in ROM from 8.1° preoperative to  5.4° postoperative with 
ProDisc II 337.  Using the DCRA method , Leivseth et al in a study from 2006 reported a range of 
motion less than 45% of the normal range two years postoperatively in the ProDisc II prosthesis 
338. Here, the postoperative ROM was 8.0° and 3.5° at the L4/L5 and L5/S1 level respectively.  
Although a different prosthesis design, Guyer et al reported no significant change in mean ROM 
two years after surgery with the Charité prosthesis and a postoperative ROM in instrumented 
segments of 6.0°339. In a review study of 9 studies reporting outcome after TDR mainly with the 
use of the SB Charitè prosthesis from 2003, de Kleuver155 noted that for those studies that 
reported mobility, the motion seemed to move with a reported average range of motion of 5°–
12°. However, mobility of the motion segment was frequently lost in these studies either 
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because of surgical arthrodesis performed as a result of clinical failure or because of 
spontaneous fusion with a bone ridge over the prosthesis.  
Although segmental range of motion after total disc replacement is a central characteristic of 
disc prosthesis, there seems to be a lack of consensus when reporting this in clinical studies. 
None of the aforementioned studies used the same method for measurement of ROM and disc 
heights. Therefore, direct comparisons across studies are difficult.  
Although clinical trials that involve total disc replacement report segmental range of motion as 
outcome criteria306,339,340, the association between postoperative mobility and clinical outcome 
has not been unequivocally established. Huang et al. reported a positive but weak correlation 
between range of motion and several clinical outcomes 227. Using the same statistical methods 
for comparing clinical outcome with range of motion, we were unable to reproduce the results 
of Huang et al in study III. We conclude that total disc replacement did not lead to increased 
lumbar motion compared to the natural history of degenerative disc disease and while 
segmental motion increased marginally but non-significantly and disc height increased 
significantly in the prosthesis cohort, these two parameters remained virtually unchanged in the 
rehabilitation cohort. Nevertheless, clinical outcomes improved in the rehabilitation as well as 
the prosthesis cohort, though to a lesser extent. This observation suggests that segmental 
motion and disc height are not major determinants of clinical outcome.  
We suggest four possible explanations for the low mobility of the segments instrumented with 
disc prostheses found in study III: 
Surgical procedure. When implanting disc prosthesis in lumbar segments, release of fibrotic and 
contracted anterior structures (ligaments, annulus fibrosus) occurs. The extent of the release of 
the posterior structures is more open to variation. While motion of the prosthesis is 
semiconstrained, the stiffness of the posterior tissues might hinder flexion of the segment-
prosthesis complex.  
Location of the axis of rotation. Restriction of motion would be expected if the axis of rotation of 
the artificial joint did not coincide with the physiological axis of rotation. In situ, the centre of 
rotation of the ProDisc prosthesis is located approximately 5 mm below the cranial endplate of 
the caudal vertebra. Thus there is a small misalignment of the prosthesis axis with respect to the 
physiological axes of rotation of the L4/L5 and L5/S1 joints as determined by Penning et al. 341  
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Disc height. In L5/S1 segments instrumented with disc prostheses, the change in disc space 
height from pre- to post-treatment amounted to 3.2 SD on average. For L5/S1 one SD equals 
approximately 10% of disc height or approximately 1.2 mm.11 Thus a 3.2 SD amounts to 
approximately 4 mm, equivalent to 1/3 of the normal disc height. It is conceivable that the 
considerable increase of the disc space after implantation could cause abnormal strain of the 
ligaments of the zygapophyseal joints and thus impede motion. However, there was no clear 
relationship found between post-treatment disc height and the range of segmental motion as 
documented in this study.  
 Natural course. A forth reason for the low mobility of instrumented segments could be the 
natural course of the degenerative disease itself. Several studies report decreased segmental 
ROM at the most severe stages of disc degeneration146. 
What remains unanswered in our study is if the small range of motion in the prosthesis after two 
years could prevent adjacent level disease (if this is an issue). In a study of segmental motion in 
155 implanted ProDisc L prostheses, Auerbach342 et al showed that patients with TDR lost slight 
relative contribution to total lumbar motion from the operative level which was mostly 
compensated for by the caudal adjacent level.  In a separate study, we showed that ALD was 
observed at similar frequencies in the two treatment groups in this study at the 2-year follow-up. 
However, the surgery group had increased facet arthropathy at the implant level 343.  
Although the development of adjacent level disease is a central issue in fusion and TDR surgery, 
it is  likely that degenerative disc disease is a multisegmental, progressive disease caused by a 
genetic predisposition or a tissue response to an insult or altered mechanical environment17,18. 
The primary rationale for inserting a mobility preserving device, the prevention of development 
of adjacent level disease171, thus remains controversial. The phenomenon called Adjacent Level 
Disease could be dependent on which model is used to analyse range of motion 344,345. A recent 
study using non-linear finite element model suggests that fusion surgery with stand-alone 
interbody cage could even reduce stress on adjacent levels181 . 
5.2.4 Difference in efficacy measures of health in economical trials 
To assess if surgery with total disc replacement could be cost effective, we used several 
statistical and graphical methods that are well recognized, up to date and recommended by the 
Norwegian authorities 193,198,346. Using these methods, it was difficult to assess if surgery with 
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total disc replacement could be cost effective because this varied with the use of clinical 
effectiveness outcome measurement. The discrepancy between the two utility indexes revealed 
in study II and IV could partly be explained by the method of which utilities are estimated. Two 
important differences between these two techniques are often mentioned: First, using the SG  
(Standard Gamble - SG)  method, people are asked to take a risk while the TTO (Time Trade Off – 
TTO)  are riskless. Second, while the TTO method assumes that utility is linear in duration, the SG 
method has no restriction on the utility function for the duration of the health state 347,348. Partly 
as a result of this, the health states utilities of EQ5-D (TTO) and SF6-D (SG) show systematically 
different utilities 193,198,348-350. The TTO method tends to produce lower utility values than the SG 
method)351. This could be observed looking at the baseline utility values of the present study. 
Also, a floor effect of SF-6D and a ceiling effect of EQ5-D has been observed 352. This could also 
be observed in the Rasch analysis in study 4.  
No standardized recommendation for the use of utility indices exists. However, several studies 
report that assessment of cost-effectiveness could be dependent on the index used as confirmed 
in study II and IV by our study267,353-355.  The problem with choice of utility index and outcome of 
a cost utility analysis exists also in other clinical settings356. In a paper from 2011, Whitehurst et 
al discuss the differences of EQ-5D and SF-6D on a group mean score level 357. They found that 
the same pattern of difference between the two utility indexes can be found on a group level as 
well as on an individual level: The SF-6D provides higher score values for poorer health states 
while EQ-5D provides higher score values for milder health states and that the two indexes 
cannot be used interchangeably. The practical consequences of the latter is that the effect of 
treatments could be overestimated and new treatments falsely accepted as cost effective when 
they are not 355,358.  
One of the main issues of reporting health economic outcomes in clinical trials is to inform 
decision makers so that priorities of scarce health resources can be made 194. In order to 
compare and prioritize across disease conditions, it is important to use a generic as opposed to a 
disease specific outcome measure 207,237. A central question becomes this:   
What is the pay-off for using generic as opposed to disease specific instruments? 
The EQ-5D is one of the most widely used generic instruments for assessing efficacy in cost-
effectiveness studies and specifically,  it is thought to be adequate when reporting efficacy in 
health economic trials of CLBP patients 255,257,359. The validity and reliability of EQ5-D generally 
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and for back pain patients specifically is documented in several papers 360-362. For this reason, the 
EQ-5D was chosen as the main outcome variable in study II. The SF6-D utility index is based on 
the SF-36 questionnaire for generic health related quality of life 206.  The SF-36 is known to have 
relatively good responsiveness properties (ability to detect change in health status after 
treatment) when compared to disease specific questionnaires like the ODI 236. Specifically, the 
combined pain and function scale from SF-36 have been reported to have a high level of 
sensitivity and specificity in identifying improvement after treatment 236,255,256. Djurasovic363 in a 
recent study of outcome after fusion surgery showed that the health dimensions pain intensity, 
walking, and social life measured by the ODI, best predicted improvement in overall health-
related quality of life, as measured by using the physical component score of the SF-36. Generic 
instruments in general are known to be less sensitive to change of health conditions after 
treatment compared to disease specific instruments 236,237,364. The more specific the outcomes 
tool, the more sensitive the response 255. In study IV, we found that the responsiveness was 
higher for the SF-6D than the EQ-5D. However, the criterion validity for the indices (their 
similarity with the gold standard, the ODI) were lower for the SF-6D than the EQ- 5D. In 
comparative studies like the present, the ability to detect if the treatment has caused a change 
may be the most important property of an instrument. This might favor the SF-6D in such 
studies. 
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6 CONCLUSIONS 
We found a statistical significant difference in the main outcome variable (ODI)   in favor of disc 
prosthesis surgery when compared to non-surgical treatment. However, we were not able to 
verify that this difference was clinically meaningful.  A clinical significant improvement in quality 
of life related to low back pain was found in both treatment groups in the per protocol analysis 
using a mixed model analysis. Disc prosthesis surgery is subject to potentially severe 
complications and our results indicate that non-surgical treatment should be the first treatment 
option.  
Total disc replacement surgery was cost effective compared non-surgical treatment using EQ-5D 
as efficacy outcome. However, cost-effectiveness in this study was dependent on the utility 
index used to evaluate effectiveness. When SF-6D was used as an efficacy outcome variable, disc 
prosthesis surgery was not cost-effective. This introduces an element of arbitrariness when 
assessing cost-effectiveness in cost-utility studies and underscores the need for a clear 
statement from health authorities to guide further health economic trials. 
In segments with inserted prosthesis, we were not able to show any significant change in 
segmental mobility from preoperative to two year postoperative. There was no significant 
difference in segmental motion comparing operated segments with segments at the same levels 
in the non-surgical treatment group. Furthermore, no correlation was found between movement 
in the prosthesis and clinical outcome.  
The difference in important measurement properties between two of the most used measures 
of effectiveness (utility indices) in health economic trials were too large to consider them 
interchangeable. Because it could have a great impact on the probability of acceptance of a new 
treatment as cost-effective or not, this underscores the importance of choosing the right clinical 
outcome measurement when reporting results in cost-effectiveness studies.  
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Future research 
In a recent double-blind RCT Albert et al 365 tested  the efficacy of antibiotic treatment in 
patients with chronic low back pain ([6 months) and Modic type 1 changes in the IVD. Patients 
were randomized to either 100 days of antibiotic treatment (Bioclavid) or placebo and were 
blindly evaluated at baseline; end of treatment and at 1-year follow-up.  The antibiotic group 
improved highly statistically significant on all outcome measures and improvement continued 
from 100 days follow-up until 1-year follow-up. However, further studies are needed to confirm 
this. A Norwegian study is being planned randomizing patients either to antibiotics or to palcebo 
(Bjørn Skogstad, personal communication). If confirmed, this opens up for a radically new 
perspective in the treatment of degenerative disc disease and low back pain. 
Biological intervertebral disc replacement in the field of tissue engineering is another approach 
to the problem 366. This includes the introduction of functional cells and supporting biomaterials 
with cells, cells plus biomaterial or biomaterial alone into the degenerate disc366-369. Inkjet 
printing of 3-D hydrogel structures used as scaffolds for various cell types are also described370-
372.  Here, a soft scaffold is fabricated according to a computer-aided design template using a 
single device in what is called “computer aided scaffold topology design”373. It should be noted 
that studies in this field is partly motivated by the notion that total disc replacement surgery is 
“…very traumatic and that the non-biological prosthesis wears with time”366 and also the believe 
that fusion surgery can cause adjacent level disease160,366,374. 
Novel MRI techniques, such as quantitative MRI, T1ʌ MRI, sodium MRI and nuclear magnetic 
resonance spectroscopy, are more sensitive in quantifying the biochemical changes of disc 
degeneration, as measured by alteration in collagen structure, as well as water and proteoglycan 
loss 24,375. These methods may be helpful in the struggle to establish further the connection 
between degenerative disc disease and low back pain.  
Finally, in order to evaluate the long term effect of TDR, we are now conducting an 8-year follow 
up of the patients in our study 376 in terms of clinical results, costs, reoperation- and revision 
rate, degenerative changes and prognostic factors. Hopefully, this will provide further valuable 
information to the choice of treatment for patients with degenerative disc disease and low back 
pain. 
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Surgerywithdisc prosthesis versus rehabilitation inpatients
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ABSTRACT
Objective To compare the efficacy of surgery with disc
prosthesis versus non-surgical treatment for patientswith
chronic low back pain.
Design A prospective randomised multicentre study.
Setting Five university hospitals in Norway.
Participants 173 patients with a history of low back pain
for at least one year, Oswestry disability index of at least
30 points, and degenerative changes in one or two lower
lumbar spine levels (86 patients randomised to surgery).
Patientswere treated fromApril 2004 to September 2007.
Interventions Surgery with disc prosthesis or outpatient
multidisciplinary rehabilitation for 12-15 days.
Main outcome measures The primary outcome measure
was the score on the Oswestry disability index after two
years. Secondary outcome measures were low back pain,
satisfaction with life (SF-36 and EuroQol EQ-5D), Hopkins
symptom check list (HSCL-25), fear avoidance beliefs
(FABQ), self efficacy beliefs for pain, work status, and
patients’ satisfaction and drug use. A blinded
independent observer evaluated scores on the back
performance scale and Prolo scale at two year follow-up.
Results The study was powered to detect a difference of
10 points on the Oswestry disability index between the
groups at two years. At two years there was a mean
difference of −8.4 points (95% confidence interval −13.2
to −3.6) in favour of surgery. In the analysis of
prespecified secondary outcomes, there were significant
differences in favour of surgery for low back pain (mean
difference −12.2, −21.3 to −3.1), patients’ satisfaction
(63% (n=46) v 39% (n=26)), SF-36 physical component
score (mean difference 5.8, 2.5 to 9.1), self efficacy for
pain (mean difference 1.0, 0.2 to 1.9), and the Prolo scale
(mean difference 0.9, 0.1 to 1.6). There were no
significant differences in return to work, SF-36 mental
component score, EQ-5D, fear avoidance beliefs, Hopkins
symptom check list, drug use, and the back performance
scale. One serious complication of leg amputation
occurred during surgical revision of a polyethylene
dislodgement. The drop-out rate was 20% (34) and the
crossover rate was 6% (5).
Conclusions Surgical intervention with disc prosthesis for
chronic low back pain resulted in a significantly greater
improvement in the Oswestry score compared with
rehabilitation, but this improvement did not clearly
exceed the prespecified minimally important clinical
difference between groups of 10 points, and the data are
consistent with a wide range of differences between the
groups, including values well below 10 points. The
potential risks of surgery and the substantial amount of
improvement experienced by a sizeable proportion of the
rehabilitation group also have to be incorporated into
overall decision making.
Trial registration www.clinicaltrial.gov NCT 00394732.
INTRODUCTION
Lowback pain is commonwith a lifetime prevalence of
about 59-84%.1 Although relatively few patients
develop chronic low back pain with disability, it repre-
sents extensive individual, societal, and financial pro-
blems. In patients who have had longstanding or
serious disabling low back pain in the previous
12 months, a third will improve and have less serious
problems during the following year.2 Most patients
who develop chronic low back pain, however, stay in
this condition for years.
Fusion of assumed symptomatic segments in
patients with chronic low back pain has been used
widely, but randomised studies comparing fusion
with non-surgical treatment indicate that a rehabilita-
tion programme can be as effective as surgery. Four
randomised studies have compared lumbar fusion
with non-operative treatment.3-7 Fritzell et al found
that fusion significantly reduced pain and disability
compared with usual care.3 Brox et al and Fairbank et
al compared fusion with a multidisciplinary rehabilita-
tion programme focusing on cognitive intervention
and supervised exercise.4-7 They found similar
improvement in pain and disability in the two inter-
vention groups.
During the past 25 years, insertion of a disc prosthe-
sis has become an option. In the four published
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randomised studies comparing disc prosthesis with
fusion, the clinical outcome of disc prosthesis was at
least equivalent to that of fusion.8-11 As surgical proce-
dures should be evaluated against non-surgical
methods,12 13 we compared the efficacy of disc prosthe-
sis and a multidisciplinary rehabilitation programme.
METHODS
Study design
A multicentre study conducted at five university hos-
pitals in Norway included patients with low back pain
and degenerative discs. Patients were included in the
period between April 2004 and May 2007 and were
treated within three months after randomisation.
They were randomised in blocks with a website hosted
by themedical faculty.Allocationwas concealed for all
people involved in the trial. A coordinating secretary
not involved in the treatment could access randomisa-
tion details on the internet. The patient and the treating
unit were informed about the allocation shortly after
randomisation. Randomisationwas stratified by centre
(the five university hospitals) and whether the patient
had had previous surgery (microsurgical decompres-
sion) or not. Independent observers collected and
entered data. Storage of data was allowed by the Nor-
wegian data inspectorate.
Participants
Patients were referred from all health regions in Nor-
way. They were recruited from local hospitals or pri-
mary care to their nearest university hospital as usual
without any supplemental recruitment attempt. An
orthopaedic surgeon and a specialist in physical medi-
cine and rehabilitation examined the patients before
enrolment. All patients were informed about the pro-
cedures and told that neither of the treatment methods
was documented as superior to the other. Eligible
patients were aged 25-55 and had low back pain as
the main symptom for at least a year, structured
physiotherapy or chiropractic treatment for at least
six months without sufficient effect, a score of at least
30 on the Oswestry disability index, and degenerative
intervertebral disc changes in L4/L5 or L5/S1, or both.
Degeneration had to be restricted to the two lower
levels. We evaluated the following degenerative
changes: at least 40% reduction of disc height,14
Modic changes type I or II, or both,15 high intensity
zone in the disc,16 and morphological changes classi-
fied as changes in signal intensity in the disc of grade
3 or 4.17 The disc was classified as degenerative if the
first criterion alone or at least two changes were found
on magnetic resonance imaging. The discs were inde-
pendently classified by two observers (orthopaedic
surgeon/radiologist). When there was disagreement,
a third observer classified the images and the outcome
was decided by simple majority.
Degeneration of the facet joints was not an exclusion
criterion, but symptoms of nerve root involvement
were. Details of further inclusion and exclusion cri-
teria, compliance with randomisation, and drop-outs
are listed in the appendix 1 on bmj.com.
Study interventions
Rehabilitation—The rehabilitation was based on the
treatmentmodel describedbyBrox et al4 and consisted
of a cognitive approach and supervised physical exer-
cise. A team of physiotherapists and specialists in phy-
sical medicine and rehabilitation directed the
multidisciplinary treatment. Other specialists, such as
psychologists, nurses, social workers, etc, could com-
plete the team. The intervention was standardised
through three seminars and videos and lecture sessions
for the treatment providers before the study. The inter-
vention was organised as an outpatient treatment in
groups at the involved university hospitals and lasted
for about 60 hours over three to five weeks. The treat-
ment consisted of lectures and individual discussions
focusing on relevant topics (such as anatomy and the
3 patients excluded shortly after randomisation†
Allocated to rehabilitation (n=87)
Started allocated intervention (n=80)
Did not start allocated intervention (n=7)
3 patients excluded shortly after randomisation†
Allocated to surgery (n=86)
Received allocated intervention (n=77)‡
Did not receive allocated intervention (n=9)
Analysed
Intention to treat (n=86)††
Per protocol (n=60)
Analysed
Intention to treat (n=86)
Per protocol (n=71)
Lost to follow-up at 6 weeks (n=8)
  Withdrew during treatment (n=6)
Lost to follow-up at 6 weeks (n=0)
Lost to follow-up at 3 months (n=0) Lost to follow-up at 3 months (n=9)
Screened for eligibility (n=605)
Randomised (n=179)
Excluded (n=426)*:
  Did not meet inclusion criteria (n=378)
  Refused to participate (n=48)
Allocation
Follow-up
Analysis
Enrolment
Lost to follow-up at 6 months (n=2)§ Lost to follow-up at 6 months (n=13)
Lost to follow-up at 1 year (n=4) Lost to follow-up at 1 year (n=14)¶
Lost to follow-up at 2 years (n=4)** Lost to follow-up at 2 years (n=14)¶
Fig 1 | Enrolment, randomisation, and follow-up of study patients, showing cumulative values at
two years. *Not enough degenerative change to satisfy inclusion criteria (n=29), degenerative
changes in more than two lower lumbar discs (n=80), Oswestry disability index score too low
(n=88), did not want to undergo surgery (n=28), did not want to participate in rehabilitation
(n=20), too much general pain (n=20), had previously been through similar training programme
(n=26), and other reasons (n=135; deformity, psoriasis arthritis, language problems,
coccygodynia, age, fracture, previous operation, tumour, spondylodiscitis, hip arthrosis).
†Coronary heart disease and heart attack some days after randomisation (n=1); obvious
exclusion criterion discovered some days after randomisation (n=50; earlier large abdominal
operation (n=1), not enough degenerative change to satisfy inclusion criteria (n=2),
degenerative changes in more than two lower lumbar discs (n=2). ‡One patient received one of
two disc prostheses because of bleeding. §One patient with serious vascular complication
underwent secondary leg amputation and was lost to follow-up. ¶One patient crossed over
between 6 months and 1 year and five patients between 1 year and 2 years. Five patients
underwent surgery with disc prosthesis and one patient with fusion. **Two patients underwent
surgery with instrumented fusion before two year follow-up. ††One patient excluded because
of missing baseline values and follow-up values
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physiological aspects of the back, diagnostics, imaging,
pain medicine, normal reactions, coping strategies,
family and social life, and working conditions), daily
workouts for increased physical capacity (endurance,
strength, coordination, and specific training of the
abdominal muscles and the lumbar multifidus mus-
cles), and challenging patients’ thoughts about, and
participation in, physical activities previously labelled
as not recommended (such as lifting, jumping, vacuum
cleaning, dancing, and ball games). Follow-up consul-
tations were conducted at six weeks, three months, six
months, and one year after the intervention. See
appendix 2 on bmj.com for detailed description of
the rehabilitation intervention.
Surgery—The surgical intervention consisted of
replacement of the degenerative intervertebral lumbar
disc with an artificial lumbar disc (ProDisc II, Synthes
Spine). The ProDisc consists of three pieces: twometal
endplates of cobalt chromiummolybdenum alloy and
a core (made from ultrahigh molecular weight poly-
ethylene) fixed to the inferior endplate after insertion.
Surgeons used aPfannenstiel or a para-median incision
with a retroperitoneal approach. A nearly complete
discectomywas performedwith removal of the cartila-
ginous endplates and a sufficient release of the poster-
ior longitudinal ligament to ensure disc space
mobilisation. A fluoroscope was used to ensure that
the prosthesis was placed in the midline and suffi-
ciently towards the posterior edge of the vertebrae.
All hospitals participating in the study used the same
artificial lumbar disc device. One surgeon at each cen-
tre had main responsibility for the operation (five cen-
tres and five surgeons). Surgeonswere required to have
inserted at least six disc prostheses before performing
surgery in the study. There were no major postopera-
tive restrictions. Patients were not referred for post-
operative physiotherapy, but at six weeks’ follow-up
they could be referred for physiotherapy if required,
emphasising general mobilisation and non-specific
exercises.
Outcome measures
The primary outcomemeasure was pain and disability
measured with version 2.0 of the Oswestry disability
index,18 translated into Norwegian and tested for psy-
chometric properties by Grotle et al.19 (Scores range
from 0 to 100, with lower score indicating less severe
pain and disability.) Secondary outcomes included low
back pain (measured with a visual analogue scale, ran-
ging from 0 (no pain) to 100 (worst pain imaginable))
and general health status assessed with SF-36 (scores
range from0 to 100, higher scores correspond to better
health status)20 21 and EQ-5D (scores range from −0.59
to 1 (1 equals perfect health)).22 For psychological vari-
ables we included emotional distress (Hopkins symp-
tom check list (HSCL-25), scores range from 1 to 4,
with lower scores indicating less severe symptoms)
and the fear avoidance belief questionnaire (FABQ)
for work and physical activity (scores range from 0 to
42 (work) and from0 to 24 (physical), with lower scores
indicating less severe symptoms).23 24 Self efficacy
beliefs for pain were registered by a subscale of the
arthritis self efficacy scale (scores range from 1 to 10
and are summarised and divided by 5; lower scores
indicate uncertainty inmanaging the pain).25Work sta-
tus was evaluated as suggested by Fritzell et al.3 (See
table A in appendix 3 on bmj.com.) We calculated a
net back to work rate, subtracting patients who went
back towork frompatientswho stoppedworking, satis-
factionwith the result of the treatment on a seven point
Table 1 | Baseline characteristics in patients with low back pain and degenerative disc
randomised to disc prosthesis surgery or rehabilitation. Figures are numbers (percentage)
unless stated otherwise
Surgery
(n=86)
Rehabilitation
(n=86)
Mean (SD) age (years) 41.1 (7.1) 40.8 (7.1)
Women 40 (47) 51 (59)
Mean (SD) duration of back pain (months) 76 (72 85 (74)
Education:
Primary school (9 years) 19 (22) 17 (20)
High school (12 years) 44 (51) 58 (67)
College 14 (16) 8 (9)
University 9 (11) 3 (4)
Mean (SD) body mass index (BMI) 25.6 (3.1) 25.5 (3.5)
Current smokers 42 (49) 37 (43)
Work status (working v not working):
Working (includes part time sick leave) 24 (28) 22 (26)
On sick leave 25 (29) 34 (41)
Rehabilitation 29 (34) 25 (29)
Disability pension 3 (4) 0
Homemaker 0 2 (2)
Unemployed 1 (1) 0
Student 3 (4) 0
Unknown 1 (1) 3 (4)
Comorbidity 20 (23) 21 (24)
Daily consumption of narcotics 23 (27) 17 (20)
Previous surgery 23 (27) 25 (29)
Mean (SD) ODI score 41.8 (9.1) 42.8 (9.3)
Low back pain score* 64.9 (15.3) 73.6 (13.9)
Mean (SD) SF-36 score:
Physical function 52.7 (17.6) 50.6 (17.7)
Role physical 25.3 (24.2 23.9 (18.7)
Bodily pain 24.9 (16.5) 24.4 (12.1)
General health 57.9 (19.7) 55.9 (19.9)
Vitality 37.8 (20.2) 33.1 (19.9)
Social function 53.0 (30.6) 57.6 (26.7)
Role emotion 72.5 (33.3) 67.6 (32.7)
Mental health 71.7 (18.0) 65.8 (18.9)
Physical component summary score 30.5 (7.1) 30.8 (6.5)
Mental component summary score 47.7 (13.0) 45.2 (13.2)
Mean (SD) HSCL-25 1.8 (0.5) 1.9 (0.5)
Mean (SD) FABQ work 25.9 (11.3) 27.4 (9.9)
Mean (SD) FABQ physical 14.1 (5.8) 12 (5.5)
ODI=Oswestry disability index (0 to 100, lower scores indicate less severe symptoms); SF-36=short form-36 (0
to 100, higher scores indicate better health status); HSCL-25=Hopkins symptom check list (for emotional
distress, scores range from 1 to 4, lower scores indicate less severe symptoms); FABQ=fear avoidance belief
questionnaire (scale ranges from 0 to 24 (physical) and from 0 to 42 (work), lower scores indicate less severe
symptoms).
*Calculated with horizontal scale ranging from 0 (no pain) to 100 (worst pain imaginable), with word anchors at
the beginning and end.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 11
Likert scale, and satisfaction with care on a five point
Likert scale.26 Further daily consumption of drugs was
registered. Patients attended for follow-up visits at six
weeks, three and six months, and one and two years
(the main end point of follow-up was at two years). At
two years we sent a questionnaire including the most
important outcome measures to 29 of the 34 patients
who were lost to follow-up (see table B in appendix 3
on bmj.com).
At the two year follow-up, two independent obser-
vers blinded to treatment evaluated patients using the
back performance scale (consists of five tests with a
score ranging from 0 to 15, worst possible)27 and the
Prolo scale (consists of functional and economic parts,
which are summed to aworst score of 2 and a best score
of 10).28 Patients were informed before this session not
to reveal the treatment received, and had tape placed
on their abdominal wall to hide the scarring from the
operation. We also carried out a full health economic
analysis, which will be reported elsewhere.
Statistical considerations
The trial was designed to have 80% power to detect a
significant difference of at least 10 points in change in
the mean Oswestry disability index score between the
intervention groups at two year follow-up.5 Baseline
standard deviation was estimated at 18.18 Considering
these assumptions and adding 25% for a multicentre
study design and 30% for possible drop-outs, we esti-
mated we required 180 patients.
Planned analyses
The main statistical analysis was in the intention to
treat population at one and two year follow-up.
According to our protocol the analysis was performed
with the assumption that patientswho droppedout had
no improvement after drop-out (last value carried for-
ward). We also determined if different centres had dif-
ferent outcomes. We used χ2 test or Fisher’s exact test
to analyse categorical variables and independent two
sided t test or analysis of variance to analyse continu-
ous variables. A significance level of 5% was used
throughout. All statistical analyses were performed
with SPSS version 16.0. We did not adjust for signifi-
cantly different baseline scores.
Unplanned analyses (analyses not recorded in the original
protocol)
We conducted a per protocol analysis for the primary
outcome variable (score onOswestry disability index).
Consistent with criteria from the Food and Drug
Administration,8 we considered an individual change
in score of at least 15 points from baseline to two year
follow-up as aminimal important change. A deteriora-
tion of 6 points in the score was considered a “change
for the worse.”29 We calculated the number needed to
treat with confidence intervals.30 A mixed model ana-
lysis was used to evaluate the effect of each efficacy
Table 2 | Treatment and complications in 77 patients with low
back pain and degenerative disc randomised to disc
prosthesis surgery
Variable Surgery group
No (%) by level of operation:
L4/L5 17 (22)
L5/S1 35 (46)
L4/L5 and L5/S1 25 (33)
Median (range) operative time (min) 165 (72-570)
Median (range) blood loss (ml) 310 (50-6000)
Mean (SD) length of hospital stay (days) 7.2 (3.6)
No with complications:
Intimal lesion in left common iliac artery* 1
Arterial thrombosis of dorsalis pedis artery† 1
Dural tear 0
Blood loss >1500 ml 4
Retrograde ejaculation (at one year) 1‡
Abdominal hernia 1
Superficial haematoma 1
Ileus 1
Temporary warm left foot 2
Temporary nausea at one year follow-up 1
Neurological deterioration:
Motor deficit at two year follow-up 0
Temporary motor deficit 0
Sensory loss at two year follow-up 2
Temporary sensory loss 4
Radicular pain at two year follow-up 2
Temporary radicular pain 4
Infection:
Superficial wound infection 0
Deep wound infection 0
Urinary tract infection 0
TotalNo (%)complicationsduring twoyear follow-up 26 (34)
Additional spinal surgery within 2 years:
Fusion 2§
Other 2¶
*Repeat surgery with insertion of new polyethylene inlay.
†Associated with temporary slightly colder foot at follow-up.
‡One patient reported retrograde ejaculation at baseline but not at one
year follow-up, one at baseline and at follow-up, and one at follow-up
but without baseline information.
§Fusion at level with disc prosthesis and level above.
¶Resection of spinous process because of possible painful contact
between adjacent levels.
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Fig 2 | Primary outcome variable within intention to treat
mixed model analysis. Mean difference in Oswestry disability
index (ODI) was 6.9 points at two year follow-up, P<0.001
(adjusted for baseline index)
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variable over time and between groups. In the mixed
model patients were not excluded from the analysis of
an efficacy variable if the variable wasmissing at some,
but not all, time points after baseline. In the additional
analysis (categorical or ordinal data at two year follow-
up), missing data were not replaced. Significantly dif-
ferent baseline scores were not adjusted for in the long-
itudinal model. Each outcome variable was adjusted
for the baseline values of the variable.
RESULTS
Of the 605 patients screened for eligibility, 173 were
included in the study and treated between April 2004
andSeptember 2007 (86with surgery and87with reha-
bilitation) (fig 1). The drop-out rate from inclusion to
two year follow-up was 20% (n=34) (15% (n=13) in the
surgical arm and 24% (n=21) in the rehabilitation arm).
Five patients (6%) crossed over from rehabilitation to
surgery, but none crossed from surgery to rehabilita-
tion.Of the 34 patients lost to follow-up, 26 answered a
questionnaire two and a half to five years after treat-
ment (see table B in appendix 3 on bmj.com).
Patients’ characteristics
Most baseline characteristics were similar in the two
treatment groups (table 1). Low back pain score and
SF-36 mental health subscores, however, were signifi-
cantly worse in the rehabilitation group than in the sur-
gery group.
Surgical treatment and complications
Of the patients randomised to surgery, 25 (33%) under-
went two level surgery. Median surgical time was
165 minutes (range 72-570 minutes) and median
blood loss was 310 ml (range 50-6000 ml) (table 2).
Four patients had bleeding of more than 1500 ml.
Six patients (8%) had complications resulting in
impairment at two year follow-up, and the reoperation
rate was 6.5% (n=5) (table 2).One patient had a serious
complication: at the three month follow-up, the poly-
ethylene inlay was found to be dislodged. During revi-
sion surgery, injury to the left common iliac artery led
to compartment syndrome resulting in a lower leg
amputation. One patient reported retrograde ejacula-
tion at one year follow-up. At two year follow-up, two
patients reported sensory loss in the thigh and two
patients reported new radicular pain. In addition, one
patient had an arterial thrombosis of the dorsalis pedis
artery, which temporarily resulted in a slightly colder
foot. Table 2 presents further complications. Two
patients had an additional fusion and two patients
had partial resection of the spinous processes because
of persistent back pain.
Primary outcome
Planned analyses according to protocol
The mean change Oswestry disability index score
frombaseline to two year follow-upwas 20.8 (95% con-
fidence interval 16.4 to 25.2) in the surgery group and
12.4 (8.5 to 16.3) in the rehabilitation group (table 3).
Themean treatment effect (difference between groups)
at two year follow-up was −8.4 (−13.2 to −3.6) in the
intention to treat analysis (last value carried forward).
Subgroup analysis showed no differences in the main
outcome variable between centres and level(s) oper-
ated on.
Unplanned analyses
In the mixed model analysis, the Oswestry score
improved significantly more in the surgical group
than in the rehabilitation group at all time points, in
both the intention to treat (fig 2) and per protocol ana-
lyses (table 4). The mean change from baseline to two
year follow-up was 22.5 (intention to treat) (95% con-
fidence interval 18.5 to 26.4) in the surgery group and
15.6 (intention to treat) (11.7 to 19.5) in the rehabilita-
tion group. The mean treatment effect (difference
between groups) at two year follow-up was 6.9 (2.1 to
11.7) in the intention to treat analysis. In an analysis in
Table 4 | Unplanned analysis of primary outcome in patients with low back pain and degenerative disc randomised to disc
prosthesis surgery or rehabilitation. Mean (SD) outcome values on Oswestry disability index (ODI) at follow-up and
treatment effect (difference (95% confidence interval)), minus values indicating larger improvement in outcome with surgery
Intention to treat analysis Per protocol analysis
Surgery Rehabilitation Treatment effect Surgery Rehabilitation Treatment effect*
Baseline 41.8 (9.1) 42.8 (9.3) — 42.2 (9.2) 42.1 (8.3) —
6 weeks 31.5 (17.2) 30.2 (13.6) 1.3 (−3.5 to 6.1) 31.1 (17.3) 29.6 (13.5) 1.7 (−3.1 to 6.6)
3 months 21.5 (14.1) 30.6 (13.1) −9.1 (−13.9 to −4.3) 20.7 (13.5) 30.3 (12.7) −9.5 (−14.4 to −4.6)
6 months 21.4 (16.3) 31.1 (14.9) −9.7 (−14.6 to −4.8) 20.7 (15.9) 29.9 (14.6) −9.2 (−14.2 to −4.2)
1 year 20.3 (17.2) 29.2 (16.1) −8.9 (−13.8 to −4.0) 19.7 (16.4) 27.0 (15.0) −7.3 (−12.3 to −2.3)
2 years 19.8 (16.7) 26.7 (14.5) −6.9 (−11.7 to −2.1) 18.8 (15.8) 26.9 (13.9) −8.1 (−12.9 to −3.2)
ODI=see footnote for table 1 for scale details.
*All P<0.001 for trend in treatment effect over time. Two sided t test.
Table 3 | Planned analysis of primary outcome in patients with low back pain and
degenerative disc randomised to disc prosthesis surgery or rehabilitation. Mean (SD)
outcome values on Oswestry disability index (ODI) at 12 and 24 months and treatment effect
Mean outcome
Treatment effect* (95% CI) P value†Surgery Rehabilitation
Baseline 41.8 (9.1) 42.8 (9.3) — —
1 year 22.3 (17.0) 33.0 (16.6) −10.0 (−15.0 to −5.0) <0.001
2 years 21.2 (17.1) 30.0 (16.0) −8.4 (−13.2 to −3.6) 0.001
ODI=see footnote for table 1 for scale details.
*Difference between groups in mean change from baseline.
†Two sided t test.
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which the patient with lower leg amputation was given
worst score in the group, the difference between the
groups remained significant (P<0.001). Some 70%
(n=51) of the patients in the surgery group and 47%
(n=31) of the patients in the rehabilitation group had
an improvement inOswestry score of at least 15 points
(P<0.006) (intention to treat). The number needed to
treat was 4.4 (2.6 to 14.5). Worsening of low back pain
was experienced by 11% (n=8) of the surgical group
and 9% (n=6) of the rehabilitation group. Subgroup
analysis showed no differences in the main outcome
variable between centres and level(s) operated on.
Secondary outcomes
Planned analyses according to protocol
Low back pain, SF-36 physical summary, and patients’
satisfaction improved significantlymore in the surgical
group than the rehabilitation group at two year follow-
up (table 5). The mean difference between the groups
in change from baseline to two year follow-up was
−12.2 (95% confidence interval −21.3 to −3.1) for low
back pain and 5.8 (2.5 to 9.1) for SF-36 physical sum-
mary. On the seven point global rating scale at two
years, 63% (46) of patients in the surgery group and
39% (26) in the rehabilitation group (P=0.005 for dif-
ference between treatment groups) considered them-
selves completely recovered or much improved. Self
efficacy for pain favoured the surgical group. SF-36
mental summary, EQ-5D, FABQ work and physical,
HSCL-25, return to work, and drug consumption did
not differ at two year follow-up. At the start of the
study, 28% (46) of patients were at work full or part
time; at two year follow-up, this had increased to 56%
(n=74). There was a “net back to work” rate of 31%
(n=21) in the surgical group and 23% (n=15) in the
rehabilitation group (P=0.31) (table 5). Scores on the
back performance scale did not differ significantly
between the groups (−0.8, −1.8 to 0.2; P=0.10). The
Prolo sum score favoured the surgical group, with a
mean difference of 0.9 (0.1 to 1.6; P=0.019).
Unplanned analyses
In the mixed model analysis, low back pain (table 6),
SF-36 physical summary (table 8), andEQ-5D,HSCL-
25, and self efficacy for pain (table 9) improved signif-
icantly more in the surgical group than the rehabilita-
tion group at all time points. The mean difference
between the groups in change from baseline to two
year follow-up for low back pain was −12.7 (95% con-
fidence interval −21.1 to −4.2, table 6) and SF-36 phy-
sical summary 4.3 (0.8 to 7.9, table 8). Further analyses
are shown in tables 7, 8, and 9.
DISCUSSION
This randomised trial comparing disc prosthesis with
multidisciplinary rehabilitation showed a significant
difference in the primary outcome variable (Oswestry
disability index after two years) in favour of surgery.
The difference between groups of 8.4 points on the
index (with intention to treat analysis) at two year fol-
low-up, however, was smaller than the difference of 10
Table 5 | Planned analysis of secondary outcomes in patients with low back pain and
degenerative disc randomised to disc prosthesis surgery or rehabilitation. Mean (SD) values
at 12 and 24 months (unless stated otherwise) and treatment effect
Variable
Mean outcome Treatment effect
(95% CI)* P value†Surgery Rehabilitation
Back pain score‡:
Baseline 64.9 (15.3) 73.6 (13.9)
1 year 35.6 (28.6) 53.2 (28.4) −14.0 (−23.0 to −5.0) 0.003
2 years 35.4 (29.1) 49.7 (28.4) −12.2 (−21.3 to −3.1) 0.009
SF-36 physical component summary:
Baseline 30.5 (7.1) 30.8 (6.5)
1 year 42.8 (12.2) 37.3 (11.0) 5.5 (1.9 to 9.1) 0.003
2 years 43.3 (11.7) 37.7 (10.1) 5.8 (2.5 to 9.1) 0.001
SF-36 mental component summary‡:
Baseline 47.7 (13.0) 45.2 (13.2)
1 year 50.2 (12.0) 49.2 (13.2) 0.2 (−3.5 to 3.8) 0.90
2 years 50.7 (11.6) 48.6 (12.8) 1.0 (−2.4 to 4.4) 0.50
EQ-5D:
Baseline 0.30 (0.27) 0.27 (0.31)
1 year 0.68 (0.34) 0.55 (0.32) 0.13 (0.01 to 0.25) 0.04
2 years 0.69 (0.33) 0.63 (0.28) 0.06 (−0.05 to 0.18) 0.26
HSCL-25
Baseline 1.81 (0.50) 1.88 (0.51)
1 year 1.51 (0.49) 1.67 (0.52) −0.12 (−0.26 to 0.02) 0.10
2 years 1.50 (0.44) 1.63 (0.52) −0.10 (−0.23 to 0.04) 0.20
FABQ work:
Baseline 25.8 (11.2) 27.4 (27.4)
1 year 19.2 (14.2) 23.1 (13.0) −2.7 (−6.5 to 1.1) 0.20
2 years 18.1 (13.9) 21.2 (12.8) −2.1 (−6.0 to 1.7) 0.30
FABQ physical:
Baseline 14.0 (5.8) 12.5 (5.6)
1 year 8.8 (6.7) 9.7 (5.8) −1.3 (−3.2 to 0.6) 0.20
2 years 9.0 (6.8) 9.9 (6.0) −1.5 (−3.4 to 0.5) 0.10
Self efficacy:
Baseline 3.4 (1.5) 3.6 (1.6)
1 year 6.3 (3.3) 5.2 (2.4) 1.2 (0.3 to 2.1) 0.01
2 years 6.1 (2.9) 5.3 (2.5) 1.0 (0.2 to 1.9) 0.02
No (%) returned to work at 2 years§: 21 (31) 15 (23) — 0.31
No (%) satisfied with outcome
at 2 years¶
46 (63) 26 (39) — 0.005
No (%) satisfied with care at 1 year** 66 (90) 48 (73) — 0.011
No (%) with drug consumption
at 2 years††
16 (22) 14 (18) — 0.30
Back performance scale at 2 years‡‡ 3.2 (3.0) 4.0 (3.0) −0.8 (−1.8 to 0.2) 0.10
Prolo scale at 2 years§§ 7.0 (2.3) 6.1 (1.9) 0.9 (0.1 to 1.6) 0.019
ED-5Q score ranges from −0.59 to 1 (1 equals perfect health); self efficacy beliefs for pain scores ranges from 1
to 10 and are summarised and divided by 5. Lower scores indicate that he/she is very uncertain if he/she is
able to manage pain. For other scores see footnote to table 1.
*Treatment effect is difference between groups in mean change from baseline. Positive value in SF-36, EQ-5D,
self efficacy for pain, and Prolo scale and negative values in remaining variables indicate larger improvement in
outcome with surgery.
†Two sided t test for continuous variables and Pearson’s χ2 test for categorical variables.
‡Values not adjusted for significantly different baseline scores.
§Net back to work rate calculated by subtracting patients who went back to work from patients who stopped
working.
¶7 point Likert scale (1=completely recovered, 2=much recovered to 7=vastly worsened); slightly improved not
included as satisfied with outcome.
**4 point global rating scale, not including slightly satisfied as satisfied with care.
††Use of drugs daily or not.
‡‡Scale comprises five tests with score ranging from 0 to 15 (worst possible).
§§Scale comprises functional and economic parts, summed to give worst score of 2 and best score of 10.
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points that the studywas designed to detect. As evident
in the confidence intervals, the data are consistent with
awide range of differences between the groups, includ-
ing values well below 10 points. There is, as far as we
know, no agreement on the size of the clinically impor-
tant difference between two treatment groups. As an
alternative we can assess the proportion of patients
achieving a clinically meaningful improvement.31 By
using a clinically meaningful improvement for an indi-
vidual patient of 15 points on the Oswestry disability
index,8 70% (n=51) of patients in the surgical group and
47% (n=31) of those in the rehabilitation group
achieved at least this improvement (intention to
treat). We will publish data on the estimated minimal
clinically important change elsewhere, but the changes
are in agreement with recommendations from FDA
studies. As there is no consensus based agreement of
how large a difference between groupsmust be to be of
clinical importance it is impossible to conclude
whether the effect found in our study is of clinical
importance. As such a decision must be made before
a new treatment can be recommended in clinical prac-
tice; our studyunderlines the need for such a consensus
agreement.
The change in theOswestry disability index score in
our study is comparable with those seen in previous
studies. In our study, the mean score was reduced by
29% (12.4 points) in the rehabilitation group (intention
to treat analysis). Brox et al4 found a similar reduction
of 29% (12.0 points) at one year follow-up, while Fair-
bank et al6 and Fritzell et al3 observed a smaller reduc-
tion at two year follow-up (8.7 and 5.5 points,
respectively). In our study, there was amean reduction
in score of 50% (20.8 points) in the surgical arm (inten-
tion to treat analysis). Similar reductions have been
reported in other studies,8 9 11 though Zigler et al used
the “chiropractor version” of the Oswestry index.32
This questionnaire has not been sufficiently validated
and consequently it is difficult to compare the
outcome.18
It could be argued that patients who withdrew after
randomisation or dropped out during or after treat-
ment had a superior or inferior outcome.We therefore
sent a questionnaire to such patients. The nine patients
whowithdrew after surgery experienced a reduction in
Oswestry score of 30.2 (SD 4.5) points. The six who
withdrew after rehabilitation had a reduction of 11.8
(SD 3.0), and the 11 patients who withdrew without
treatment had no change (1.0 (SD 4.5) points) (see
table B in appendix 3 on bmj.com). Thismight support
the assumption of no improvement in outcome after
drop-out, justifyinguse of the last value carried forward
analysis.
Most changes in secondary variables measuring dis-
ability and pain favoured surgical treatment, though
there were no significant differences between groups
in FABQ work, FABQ physical, SF-36 mental health,
EQ-5D, HSCL-25, drug consumption, return to work,
and the back performance scale in themain analysis. In
the surgical group we found a similar “net back to
work” rate as reported by Fritzell et al.3 Nevertheless,
it has been argued that sick leave, to a large extent, is
influenced by factors outside the domain of medical
and therapeutic interventions.33 The somewhat smaller
difference between groups in the back performance
scale than in the Oswestry disability index might be
explained by differences in psychometric properties
between the outcome measurements or by patients
overstating the effect in a subjective questionnaire.
Table 6 | Unplanned analysis in secondary outcome in
patients with low back pain and degenerative disc
randomised to disc prosthesis surgery or rehabilitation.
Mean (SD) outcome values for back pain* at follow-up and
treatment effect (difference (95% confidence interval))
Intention to treat analysis
Surgery Rehabilitation Treatment effect†
Baseline 64.9 (15.3) 73.6 (13.9) —
6 weeks 34.7 (27.5) 51.1 (24.6) −16.5 (−24.8 to −8.2)
3 months 29.3 (25.0) 55.4 (23.4) −26.2 (−34.5 to −17.8)
6 months 36.1 (28.5) 50.0 (24.5) −13.8 (−22.3 to −5.3)
1 year 33.0 (29.4) 48.7 (28.9) −15.7 (−24.3 to −7.0)
2 years 32.7 (28.8) 45.3 (28.6) −12.7 (−21.1 to −4.2)
*See table 1 for score details.
†Negative values indicate larger improvement in outcome with surgery.
All P<0.001 for trend in treatment effect over time. Two sided t test.
Table 7 | Unplanned analysis in secondary outcomes in patients with low back pain and degenerative disc randomised to disc prosthesis surgery or
rehabilitation. Mean (SD) outcome values for SF-36*
Variable
Baseline 3 months 6 months 1 year 2 years
P value†Surgery Rehabilitation Surgery Rehabilitation Surgery Rehabilitation Surgery Rehabilitation Surgery Rehabilitation
Physical function 52.7 (17.6) 50.6 (17.8) 76.2 (18.3) 64.0 (22.4) 76.0 (21.4) 63.7 (21.0) 79.5 (20.6) 66.7 (22.9) 78.9 (20.2) 69.6 (22.2) <0.001
Role physical 25.3 (24.2) 23.9 (18.7) 50.0 (31.5) 45.6 (31.9) 57.2 (35.1) 47.8 (31.2) 58.9 (37.3) 55.9 (33.9) 66.4 (33.5) 55.1 (35.0) 0.135
Bodily pain 24.9 (16.5) 24.4 (12.1) 48.2 (22.4) 34.9 (16.1) 50.8 (29.1) 39.1 (20.8) 52.5 (30.8) 43.5 (24.6) 55.5 (29.1) 44.4 (23.0) <0.001
General health 57.9 (19.7) 55.9 (19.9) 67.6 (22.8) 60.7 (24.7) 65.5 (24.3) 60.1 (24.4) 68.1 (26.8) 61.7 (22.1) 65.7 (26.0) 61.1 (24.8) 0.125
Vitality 37.8 (20.2) 33.1 (20.0) 50.3 (21.6) 44.4 (22.1) 55.6 (23.7) 45.7 (22.9) 57.5 (27.5) 48.2 (24.9) 55.0 (27.1) 46.8 (23.5) 0.003
Social function 53.0 (30.6) 57.6 (26.7) 72.8 (25.0) 68.8 (25.6) 75.0 (28.6) 71.1 (26.7) 76.7 (25.7) 74.3 (26.8) 78.3 (26.8) 77.9 (27.4) 0.725
Role emotion 72.5 (33.3) 67.6 (32.7) 85.1 (23.3) 69.0 (34.7) 83.3 (26.3) 74.5 (29.8) 80.4 (31.0) 79.2 (26.3) 83.9 (25.6 ) 79.2 (29.0) 0.010
Mental health‡ 71.7 (18.0) 65.8 (18.7) 78.6 (15.6) 72.4 (17.9) 79.5 (16.8) 74.1 (16.4) 80.4 (17.5) 73.8 (20.9) 78.3 (18.2) 75.8 (17.5) 0.007
*See table 1 for score details.
†For trend in treatment effect over time.
‡Values are not adjusted for significantly different baseline scores.
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Strengths and limitations
Our studyhas several strengths. It was randomised and
had few patients who crossed over to the other treat-
ment regimen. In addition, an independent research
assistant collected the data, the observers at the two
year evaluation were blinded, the interventions were
standardised, and the financing of the studywas public.
Choosing magnetic resonance imaging criteria for
inclusion could be a strength or limitation. To our
knowledge, there are no specific criteria to determine
which degenerative changes should be operated on.
When designing the study we wanted the inclusion of
patients across centres to be as unanimous as possible,
treating the same population, although this possibly
would lead to less external validity of the study. It
could also possibly lead to inclusion of more severe
degenerated discs in our study compared with other
studies.8 9
One limitation of our study is the lack of a placebo or
sham group. The regression to the mean and the nat-
ural resolution of chronic low back pain must also be
considered in both groups. When balancing a non-
operative regimen with an operative treatment, there
is probably a difference in placebo effect that is difficult
to untangle from the treatment effect.34-37 The placebo
effect might be higher in the surgical group, although
the possible placebo effect of rehabilitation over sev-
eral weeks with personal contact with a therapist
should not be underestimated. Furthermore, it could
be argued that the patients included in the study
wanted surgery, but the number of patients not want-
ing the rehabilitation programme was similar to the
number of patients not wanting surgery (see figure
and appendix 1 on bmj.com). Brox et al found no dif-
ference in treatment effect between patients who did
and did not “believe” in surgery,4 5 and a recent study
found no significant relation between baseline
expectations and follow-up scores.38 On the other
hand, “expectation being fulfilled” might be a predic-
tor of global outcome.38 During the inclusion process,
we emphasised the advantages and disadvantages of
the two treatment options and that none of the treat-
ments are documented as superior to another. It is still
possible, however, that patients in the rehabilitation
group found themselves faced with “more of the
same.”The lack of routine rehabilitation in the surgical
arm could be another limitation in the study. We
wanted to avoid the postoperative treatment contain-
ing elements from the rehabilitation programme.
Hence, patients received only general advice when
they were discharged from the hospital and received
no rehabilitation in the first weeks after surgery. At
six weeks, however, patients could be referred if
required to a physiotherapist at their home for func-
tional mobilisation and general muscle training.
Table 8 | Unplanned analysis in secondary outcome in
patients with low back pain and degenerative disc
randomised to disc prosthesis surgery or rehabilitation.
Mean (SD) outcome values for physical and mental
component summary scores on SF-36* at follow-up and
treatment effect (difference (95% confidence interval))
Surgery Rehabilitation Treatment effect†
SF-36 physical component summary
Baseline 30.5 (7.1) 30.8 (6.5) —
3 months 40.3 (10.9) 37.3 (8.9) 3.0 (−0.6 to 6.6)
6 months 41.4 (12.3) 37.2 (9.2) 4.2 (0.6 to 7.8)
1 year 43.5 (12.7) 39.4 (11.5) 4.2 (0.6 to 7.7)
2 years 43.9 (11.9) 39.6 (10.4) 4.3 (0.8 to 7.9)
SF-36 mental component summary
Baseline 47.7 (13.0) 45.2 (13.2) —
3 months 50.9 (10.4) 47.0 (12.9) 3.9 (−0.2 to 8.0)
6 months 52.0 (9.7) 49.5 (10.5) 2.5 (−1.6 to 6.6)
1 year 51.7 (11.6) 49.7 (12.0) 2.0 (−2.0 to 6.1)
2 years 51.0 (11.0) 50.5 (11.0) 0.5 (−3.4 to 4.5)
*See table 1 for score details.
†Positive treatment effect indicates larger improvement in outcome for
surgery. P=0.002 for physical and 0.166 for mental for trend in treatment
effect over time.
Table 9 | Secondary outcomes in patients with low back pain
and degenerative disc randomised to disc prosthesis surgery
or rehabilitation. Mean (SD) outcome values on EQ-5D, HSCL-
25, FABQ, and self efficacy at follow-up and treatment effect
(difference (95% confidence interval))
Variable* Surgery Rehabilitation Treatment effect†
EQ-5D‡
Baseline 0.30 (0.30) 0.27 (0.31) —
6 weeks 0.59 (0.30) 0.55 (0.29) 0.04 (−0.06 to 0.15)
3 months 0.70 (0.23) 0.48 (0.31) 0.22 (0.12 to 0.33)
6 months 0.68 (0.28) 0.51 (0.33) 0.17 (0.06 to 0.27)
1 year 0.67 (0.35) 0.54 (0.32) 0.13 (0.02 to 0.23)
2 years 0.68 (0.34) 0.60 (0.30) 0.08 (−0.03 to 0.18)
HSCL-25§
Baseline 1.81 (0.50) 1.88 (0.51) —
3 months 1.38 (0.34) 1.66 (0.51) −0.27 (−0.44 to −0.11)
6 months 1.44 (0.45) 1.66 (0.49) −0.22 (−0.38 to −0.05)
1 year 1.45 (0.50) 1.59 (0.49) −0.14 (−0.30 to 0.03)
2 years 1.47 (0.49) 1.55 (0.50) −0.09 (−0.25 to 0.08)
FABQ work§
Baseline 25.8 (11.2) 27.4 (9.9) —
3 months 20.0 (12.9) 24.3 (11.9) −4.3 (−8.6 to 0.1)
6 months 18.7 (12.9) 23.0 (12.7) −4.3 (−8.7 to 0.1)
1 year 18.2 (13.9) 21.3 (13.2) −3.1 (−7.4 to 1.2)
2 years 16.7 (13.5) 18.5 (12.5) −1.8 (−6.1 to 2.5)
FABQ physical§
Baseline 14.0 (5.8) 12.5 (5.6) —
3 months 8.8 (5.3) 9.1 (6.3) −0.3 (−2.4 to 1.7)
6 months 8.6 (6.3) 9.3 (6.7) −0.7 (−2.8 to 1.3)
1 year 8.0 (6.3) 8.9 (5.8) −0.8 (−2.9 to 1.2)
2 years 8.0 (6.0) 8.3 (5.7) −0.3 (−2.3 to 1.7)
Self efficacy‡
Baseline 3.4 (1.5) 3.6 (1.6) —
3 months 6.1 (2.3) 5.0 (2.2) 1.0 (0.2 to 1.9)
6 months 6.0 (2.6) 5.6 (2.4) 0.5 (−0.3 to 1.3)
1 year 6.4 (3.3) 5.5 (2.5) 0.9 (0.0 to 1.7)
2 years 6.2 (2.7) 5.6 (2.7) 0.5 (-1.4 to 2.8)
*See tables 1 and 5 for score details.
†EQ-5D P<0.001, HSCL P<0.001, FABQ work P=0.057, FABQ physical
P=0.548, self efficacy P=0.019 for trend in treatment effect over time.
‡Positive scores indicate larger improvement in outcome with surgery.
§Negative scores indicate larger improvement in outcome with surgery.
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Furthermore, some surgical patients underwent a sec-
ond operation but repeat rehabilitationwas not consid-
ered. Patients did not request a second chance for
rehabilitation, though they were advised during fol-
low-up consultations. Another weakness in our study
is the difference in compliance between groups and the
high drop-out rate. This difference in adherence to the
protocol probably leads to an underestimate of the true
effect of surgery, especially in the intention to treat ana-
lysis. In similar studies comparing surgerywith rehabi-
litation, the drop-out rates were similar to ours.6 39-41
The patients we included in our study were highly
selected, with one or two level degenerative changes
and good general health. Thus, our results are valid
only in similar patients. Furthermore, we examined
several secondary outcome variables that could lead
to the detection of differences by chance. Although
we conducted several unplanned analyses (not
recorded in the original protocol), in common with
similar studies, we consider it as an important asset to
our data. Lately, similar studies have applied repeated
measurements by using mixed models.40 Using
unplanned analysis could be considered a weakness,
but our findings in these analyses support our main
analyses and strengthen our conclusion. Nevertheless,
caution should be used in interpreting the results of
non-prespecified analyses.
Potential harms of disc prosthesis surgery
Surgery carries a risk of serious complications, as seen
in one of our patients. In a review by Inamasu et al, the
perioperative vascular injury rate for anterior lumbar
interbody fusion was 0-18% (mean 3%).42 This is an
important drawback of surgery. No major differences
in complication rates between insertion of a disc pros-
thesis and fusion have been found in a randomised
setting.8 9 11 The short term reoperation rate in our
study was 6.5% (n=5) and the vascular injury rate was
6.5% (n=5) (table 2). Although vascular complications
are reported, serious consequences like amputation
and mortality are rare.43 Recently Kurtz et al looked
at the rates of short term revision and mortality total
disc replacement.43 They found similar reoperation
rates as with anterior fusion surgery and hip arthro-
plasty. Four retrospective studies have reported long
term reoperation rates of up to 13%.44-47 Data on the
anterior revision rate of the prosthesis is difficult to
extract from these studies but seems considerably
lower. The potential long term revision rate with a
higher complication rate on revisions needs to be
considered.48
Earlier addressed but unresolved questions are the
incidence of adjacent level degeneration after total disc
replacement and distinct characteristics of patients
associated with good outcome. Some studies have
examined these issues but more information is
needed.49-51 In a univariate analysis we found indica-
tions that patients with Modic I or II changes have a
superior result in the surgical arm and that patients
with high Oswestry scores seem to be more suitable
for rehabilitation. A full multivariate analysis of good
outcomes will be published soon to answer these ques-
tions. Another important issue is the incidence of
degeneration in the facet joints of the operated level.
An analysis of adjacent level degeneration and degen-
eration of the operated level in addition to a full health
economic analysis will be published later.
The total blood loss and operation time were higher
in our study than in similar studies. The learning curve
might be quite flat, and perhaps the participating sur-
geons should have carried out disc prosthesis surgery
in more patients before the start of the study. Using a
surgeon to expose the disc (access surgeon), might also
have reduced the blood loss and operation time. Blu-
menthal et al and Zigler et al performed one level sur-
gery, while a third of our patients underwent two level
surgery.8 9 This could explain some of the increased
blood loss and operation time in our study. Because
of the complexity of the surgery and the risk of serious
complications, we think this kind of surgery should be
confined to a few specialist centres with experienced
spine surgeons and available vascular surgeons. A
high quality rehabilitation programme should be avail-
able.
Our study was not designed to evaluate specific
mechanisms of reduction of pain and disability. Possi-
ble explanations for the pain reduction are removal of
the disc in the surgical group and better coping in the
rehabilitation group, but the patients were heteroge-
neous and probably had a mixed aetiology difficult to
separate. Even thoughwedid not have a control group,
themixed causes of chronic low back pain, the associa-
tion of surgery with potentially serious complications,
and the considerable improvement in the rehabilita-
tion group suggest that it is reasonable to consider a
rehabilitation programme before surgery.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
In patients with chronic low back pain, compared with fusion, the clinical outcome with disc
prosthesis has been at least equivalent
Compared with multidisciplinary rehabilitation, improvement in disability and pain are
similar
WHAT THIS STUDY ADDS
Surgery with disc prosthesis resulted in a significantly greater improvement in scores on the
Oswestry disability index and variables measuring disability and pain, although the
difference in Oswestry score between groups was lower than the study was designed to
detect
There were no differences in return to work and several outcomes measuring mental health
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Abstract
Background: The need for cost effectiveness analyses in randomized controlled trials that compare treatment
options is increasing. The selection of the optimal utility measure is important, and a central question is whether
the two most commonly used indexes - the EuroQuol 5D (EQ5D) and the Short Form 6D (SF6D) – can be used
interchangeably. The aim of the present study was to compare change scores of the EQ5D and SF6D utility indexes
in terms of some important measurement properties. The psychometric properties of the two utility indexes were
compared to a disease-specific instrument, the Oswestry Disability Index (ODI), in the setting of a randomized
controlled trial for degenerative disc disease.
Methods: In a randomized controlled multicentre trial, 172 patients who had experienced low back pain for an
average of 6 years were randomized to either treatment with an intensive back rehabilitation program or surgery to
insert disc prostheses. Patients filled out the ODI, EQ5D, and SF-36 at baseline and two-year follow up. The utility
indexes was compared with respect to measurement error, structural validity, criterion validity, responsiveness, and
interpretability according to the COSMIN taxonomy.
Results: At follow up, 113 patients had change score values for all three instruments. The SF6D had better similarity
with the disease-specific instrument (ODI) regarding sensitivity, specificity, and responsiveness. Measurement error
was lower for the SF6D (0.056) compared to the EQ5D (0.155). The minimal important change score value was
0.031 for SF6D and 0.173 for EQ5D. The minimal detectable change score value at a 95% confidence level were
0.157 for SF6D and 0.429 for EQ5D, and the difference in mean change score values (SD) between them was 0.23
(0.29) and so exceeded the clinical significant change score value for both instruments. Analysis of psychometric
properties indicated that the indexes are unidimensional when considered separately, but that they do not exactly
measure the same underlying construct.
Conclusions: This study indicates that the difference in important measurement properties between EQ5D and SF6D
is too large to consider them interchangeable. Since the similarity with the “gold standard” (the disease-specific
instrument) was quite different, this could indicate that the choice of index should be determined by the diagnosis.
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Background
An important way of assessing the effects of treatment in
health economic evaluations is the use of utility indexes.
The outcome scores of general health-related quality of life
(HRQoL) questionnaires are stratified into different health
states [1,2] that can then be validated in a community
population [3,4]. Treatment benefit is thus expressed in a
way that allows health states that are considered less pref-
erable (0) to full health (1) to be given quantitative values.
Because these quantitative values represent a valuation or
preference of health states for the patients, they are called
utility indexes (more utility for the patient with increasing
value). When combined with a follow up period, health
utility indexes are used to calculate quality-adjusted life
years (QALYs). There are several utility indexes that could
be used, and discrepancies exist regarding which index is
most suitable [1,5]. These discrepancies could have impli-
cations for calculating cost-effectiveness when comparing
alternative treatment options for the same disease [6-10].
Two of the most widely used indexes are the EuroQuol 5D
(EQ5D) and the Short Form 6D (SF6D) [4,7].
Two papers assessed the impact that the measure has
on cost-utility estimates [8,9]. Sach et al. found that the
SF6D and EQ5D favored different treatment options for
alleviating knee pain when applying the same cost per
QALY threshold. Søgaard et al. [11] reported on the inter-
changeability of the two indexes. When plotting difference
between change scores of SF6D and EQ5D against their
average in a Bland-Altman plot , they found that the
expected between-measure variation was 0.546 [12]. They
conclude that although both indexes appear to be psycho-
metrically valid for generic assessment of long-lasting back
pain, the variation between them was too great to be con-
sidered interchangeable.
From other studies, we could hypothesize that there
would be a discrepancy between the EQ5D and SF6D
because of differences in valuing similar health states,
evidence of a floor effect in the SF6D and a ceiling effect
in the EQ5D, and because the SF6D can describe severe
health states better than EQ5D [7,13,14].
Further work is required in this field to understand
these discrepancies. Therefore, the aim of this study was
to evaluate change scores values of the EQ5D and SF6D
utility indexes in terms measurement error, structural
validity, criterion validity, responsiveness, and interpret-
ability according to the COSMIN taxonomy. The psy-
chometric properties of the two utility indexes were
compared to a disease-specific instrument, the Oswestry
Disability Index (ODI), in the setting of a randomized
controlled trial for degenerative disc disease.
Methods
Details about the RCT on which this work is based is
reported in detail in Hellum et al. [15]. Between April
2004 and September 2007, 172 patients with diagnosed
chronic low back pain and degenerative disc disease were
randomized to either surgery with total disc replacement
or multidisciplinary rehabilitation. The results from this
study have been published previously [15].
Briefly, data were collected in a multicentre random-
ized controlled trial involving the five university hospi-
tals in Norway. Inclusion criteria included age between
25 and 55 years, LBP for more than a year, degenerative
changes in the intervertebral disc in one of the two low-
est levels of the lumbar spine and an Oswestry Disability
Index score of 30% points or more. Exclusion criteria
included generalized chronic pain syndrome and degen-
eration established in more than two levels. Part of this
study was an economic evaluation of chronic low back
pain treatment. Patients were randomized to either surgery
with insertion of an artificial disc or to non-surgical treat-
ment (a multidisciplinary back rehabilitation program).
The outcomes of patients who completed the SF6D,
EQ5D, and ODI at baseline and at 2-year follow up were
included in this study.
Instruments
ODI
The ODI is a back-specific questionnaire [16,17]. Patients
rate physical disability in activities of daily living due to
low back pain in 10 questions, each of which has verbal
response alternatives. Ratings are summed to yield a score
ranging from 0 (not disabled at all) to 100 (completely
disabled). We used the Norwegian translation of the vali-
dated questionnaire (version 2.0) [18].
SF6D
The SF6D utility index is comprised of 11 items from
the SF-36 [19] that were revised into a six-dimensional
health state classification system. The six dimensions are
physical functioning, role limitations, social functioning,
pain, mental health, and vitality. It reflects a continuous
outcome scored on a 0.29–1.00 scale, with 1.00 indicat-
ing full health [3]. SF6D health states were evaluated
against a normal population using the Standard Gamble
(SG) method. We used the United Kingdom (UK) tariff
[3]. The SF6D was calculated based on the Norwegian
SF-36 (version 2) with the use of syntax files in SPSS 17
(SPSS, New York, US). The syntax files were kindly pro-
vided by Dr J. Brazier, University of Sheffield, UK.
EQ5D
For the EQ5D utility index, responses on a questionnaire
with five dimensions, each comprised of three levels, are
revised into an index with a range from −0.59–1, with
1.00 indicating full health. The 243 possible health states
on the EQ5D are evaluated against a normal population
using the time trade off method (TTO) [20,21]. We used
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the Norwegian version of the EQ5D and syntax files ob-
tained from the EQ5D society using the UK tariff to cal-
culate the index.
Seven-point scale for patient assessment
Many authors suggest a seven-point scale to assess patient
outcome in terms of a global score [22]. On the question:
“How much benefit do you think you have had from the
treatment you have received?” patients answered on a 7-
category response scale that ranged from “I am completely
disabled” to “I am completely recovered”.
Data analysis
We followed the definitions and recommendations from
The COSMIN (COnsensus-based Standards for the selec-
tion of health Measurement INstruments) checklist when
analyzing the psychometric properties of the two utility
indexes and ODI in this study [23].
If not otherwise mentioned, SPSS version 17 was used
in the statistical analysis.
Measurement error
Measurement error concerns the systematic and random
error of a patient`s score that is not attributed to true
changes in the construct to be measured [24]. We used
the standard error of measurement (SEM) to express in-
strument imprecision [22,25-27]. The advantage of using
SEM is that it is considered to be an attribute of the
measure and not a characteristic of the sample itself
[28]. The SEM value could be calculated from a test-
retest study or in a group of stable patients. The SEM in
this study was calculated as:
Sw ¼ SEM ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
2n
∑d2t
r
where sw is the within-subject standard deviation, d is the
difference between two observations in patients i who
reported “unchanged” on a four-point scale between 3 and
6 months follow up and n is the number of subjects [29].
The sw statistics is also called the SEMconsistency [30].
The lowest change that exceeds measurement error
and noise at a 95% confidence level is defined as:
MDC95 ¼ 1:96 
ﬃﬃﬃ
2
p
 SEM ¼ 2:77  SEM
Here, the *
ﬃﬃﬃ
2
p
is introduced because there are two
measurements for each patient. The minimum detectable
change (MDC) at a 95% confidence level, is denoted
MDC95 [31]. With a scale value ≥MDC95, we can be 95%
certain that a change in the measured underlying con-
struct has really occurred [32].
To assess the agreement between EQ5D and SF6D, a
Bland Altman plot was constructed. [12]. The average
EQ5D and SF6D change score values were plotted against
the mean difference in change score values of both instru-
ments. Limits of Agreement (LoA) based on a +/−
1.96*SDdifference interval for the differences were also
constructed.
Structural validity
Structural validity concerns the degree to which the scores
of an instrument are an adequate reflection of the dimen-
sionality of the construct to be measured [33]. Both EQ5D
and SF6D are constructed to measure the dimension of
general health related quality of life (HRQoL) alongside a
continuous scale (from low to high). Using Item Response
Theory (IRT), the unidimensionality of the two utility in-
dexes was tested. The category ordering of the question-
naire items (the probability of moving from an easier to a
harder accomplished category of item answers in parallel
with being increasingly disabled) was also tested.
We employed the unrestricted (Partial-Credit) poly-
tomous model of the Rasch model (for general informa-
tion about fit to the Rasch model, see Additional file 1)
and the test proposed by Smith to reveal unidimension-
ality [34]. The SF6D and EQ5D were tested for unidi-
mensionality in a principal component analysis (PCA)
[35]. We performed a test equating procedure with base-
line values from the SF6D and the EQ5D. The response
of each patient to a question was tested against what
was predicted by the Rasch model. Deviation from the
model is expressed in residuals. Independent t-tests were
used to test if the magnitude of the residuals represents
a significant deviation. The CI calculated for this was
95%. We carried out a binominal test for the proportion
of t-tests outside the range of −1.96–1.96. The software
used in the Rasch analysis was RUMM 2020 (RUMM
Laboratory Pty Ltd.).
Criterion validity
Criterion validity concerns the degree to which the
scores of an instrument are an adequate reflection of a
“gold standard” when this is present [33]. In this analysis
we compared the scores of the EQ5D and SF6D to the
disease specific instrument ODI. The rationale was that
the ODI has been found to be a responsive and valid
measure for patients with LBP [16,18,36] and that an im-
provement assessed by the ODI should be correlated
with an improvement assessed by the two utility indexes.
Spearman rank correlation coefficient (r) with 1000
bootstrap replications of the baseline scores was calcu-
lated to assess the correlation between the scores of the
EQ5D and ODI and SF6D and ODI.
Responsiveness
Responsiveness is defined as the ability of an instrument
to detect change over time in the construct to be mea-
sured [33]. Responsiveness was assessed by using the
Johnsen et al. BMC Musculoskeletal Disorders 2013, 14:148 Page 3 of 9
http://www.biomedcentral.com/1471-2474/14/148
ODI and the seven-point global scores at 2-year follow-
up as “gold standard”. First, we calculated the Spearman
rank correlation coefficient (r) with 1000 bootstrap repli-
cations for the correlation between change scores from
baseline to 2 year FU for the EQ5D, SF6D and ODI. Sec-
ond, we analyzed the area under the Receiver Operator
Curve (ROC) for the change scores of the EQ5D, SF6D
and ODI by using a dichotomization of the patient glo-
bal scores as follows: Categories 1 to 3 was considered
“improved” and categories 4 to 7 were “non-improved”.
Sensitivity was defined as the proportion of patients who
were correctly classified as “improved” and specificity
was defined as the proportion of patients who were cor-
rectly classified as “non-improved”. A receiver operating
characteristic (ROC) curve was then calculated by plot-
ting every possible change score from baseline to 2 year
FU for EQ5D, SF6D and ODI using the global score as
an anchor [37,38]. The area under the ROC curve
(AUC) was then calculated. This value corresponds to
the possibility of correctly diagnosing a patient as having
improved when this is really the case [38] and reflects
how responsive the instruments are to detect a change
in the underlying construct.
The calculation of ROC curves was performed with
MedCalc Statistica software (version 11.1.1. for Win-
dows, Brussels, Belgia).
Interpretability
Interpretability concerns the qualitative meaning of quan-
titative scores or change in scores. A core question is:
“What is the smallest change in score in the construct to
be measured which patients consider important? This is
expressed as the Minimal Important Change (MIC) value
[33], and is calculated based on the sensitivity and specifi-
city results from the ROC analysis described above. The
cut-off value for differentiating between patients with or
without improvement at optimum sensitivity and specifi-
city was determined using ROC analysis [38]. This corre-
sponds to the upper left point on the ROC curve and it
can be interpreted as the point or value that yields the
lowest overall misclassification [25,39].
Study approval
The study was evaluated and approved by the regional
Committee for Medical Research Ethics in east Norway.
Storage of data was allowed by the Norwegian Data In-
spectorate. The study was conducted in accordance with
the Helsinki Declaration and the ICH-GCP guidelines
and registered at clinicaltrial.gov under the identifier
NCT00394732.
Results
At inclusion, there were 52,6% females. Mean age was
41 years and mean (SD) duration of low back pain was 6
years (5,74). Response rates at baseline and 2-year follow
up and pre- and post-treatment scores are presented in
Table 1. At baseline, 133 out of 173 patients had com-
pletely filled out the ODI, the EQ5D, and the SF-36, so
values for each of the instruments could be calculated.
At 2-year follow up, 113 patients had values for all three
instruments, so change scores could be calculated.
Measurement error
The SEM values calculated for patients who were stable
for a period of 3 months are presented in Table 2.
The smallest change score that could be said to repre-
sent a real change beyond measurement error with 95%
probability in one individual (MDC95) are presented in
Table 2.
The proportion of patients with a change score
value ≥MCD95 was 69% for ODI, 57% for SF6D, and 45%
for EQ5D.
Figure 1 shows a Bland-Altman plot of the SF6D and
EQ5D baseline values. It illustrates a systematic variation
(proportional error) in the EQ5D and SF6D scores, with
less healthy individuals tending to have a higher score
on the SF6D and healthier individuals tending to have a
higher score on the EQ5D. The 95% Limits of Agree-
ment (LOA) varied from −0.3 to 0.83 with a mean diffe-
rence in scale scores (SD) of 0.23 (0.29).
Structural validity
When the SF6D items were used as one subset and the
EQ5D items as another, the binominal test showed over-
lap of the 5% expected value with the 95% CI for each of
the indexes. When the EQ5D and SF6D items were com-
bined on a common scale, no overlap was identified. This
finding could indicate that the indexes are unidimensional
Table 1 Response rate at baseline and two year follow up
together with pre- and post-treatment scale scores
Response rate Mean scale score (SD)
Baseline 2 years Baseline 2 year
ODI 99% 100% 42,29 (0,81) 23 (16)
SF6D 82% 90% 0.555 (0,007) 0.692 (0.143)
EQ5D 93% 99% 0.292 (0.026) 0.642 (0.318)
N = 133.
Table 2 SEM and MDC95 values
SEM MDC95
ODI 4.24 11.75
SF6D 0.056 0.157
EQ5D 0.155 0.429
The SEM represents the standard error of measurement. The MDC95 is the
minimal detectable change value that falls outside the measurement error of
the instrument with 95% probability.
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when considered separately, but that they do not exactly
measure the same underlying construct [34,40].
Figures 2 and 3 are graphic representations of the
targeting of the SF6D and EQ5D items. Patients “ability”
(level of health-related quality) and the item location
(moving from an easy to a more difficult category of
item answers in parallel with being increasingly disabled)
are plotted on the same logarithmic scale. The bars in
the top panels represent patient responses, and the bars
in the bottom panels represent item thresholds on the
scales. A threshold is the 0.5 probability point between ad-
jacent item categories [41]. HRQoL levels (i.e., scoring
values) decrease from left to right. Scoring responses out-
side the range of items represent a floor effect (to the right)
or a ceiling effect (to the left). Responses outside the range
of the scale give no additional information, and the test
cannot discriminate between patients who fall in this area.
From Figures 2 and 3 it can be seen that the EQ5D
was relatively well targeted for this group, with no sign
of floor or ceiling effects, i.e., all responders were cap-
tured within the scale. With a mean person-location
value of −0.132, the patients were at a slightly higher
level of HRQoL than the scale could express. No floor
or ceiling effect could be seen in the SF6D, but here the
mean person-location was 1.423. This indicates that
there is a tendency for patients to score at the lower end
of the scale of this index.
Three of the items in the SF6D showed disordered
threshold: question 1: Physical functioning, question 2:
Role limitation and question 4: Pain. A better fit to the
model was achieved if some of the response categories
of these items were omitted. None of the questions in
the EQ5D showed disordered thresholds.
Criterion validity
The correlation between baseline scores of ODI and
EQ5D was r = 0,58 (n = 114, p=0.000) and for ODI and
SF6D: r = 0.38 (n = 114, p = 0.000).
Responsiveness
a) The correlation between change scores of ODI
and EQ5D was r = 0,64 (n = 108, p=0.000) and
between ODI and SF6D change scores: r = 0.77
(n = 108, p = 0.000).
b) Spearman’s rho for the correlation between change
scores of the instruments and global score categories
was 0.84, 0.55 and 0.76 for ODI, EQ5D and SF6D
respectively. The area under the ROC curve, the
possibility of correctly discriminating between
“improved” or “non-improved” patients with a 95%
CI was: 94% (87.5–97.6) for ODI, 90% (82.1–94.6)
for SF6D, and 83% (75–90) for EQ5D. The ROC
curves are presented in Figure 4.
Interpretability
The MIC values defined as the most optimal cut-off
point of change scores plotted on the ROC curve was
for ODI: 12.88,(sensitivity 88%, specificity 85%), EQ5D:
Figure 1 Bland-Altman plot.
Figure 2 Person-item threshold distribution for EQ5D.
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0.173 (sensitivity: 73%, specificity 79%) and SF6D: 0,031
(sensitivity 93%, specificity 78%) (Figure 4).
Discussion
The present study failed to show similarity between
EQ5D and SF6D in several important measurement
properties. EQ5D had a higher value of inherent meas-
urement error than SF6D. The mean difference between
baseline score values had a wide 95% Limits of Agree-
ment in the Bland-Altman plot signifying a low degree
of agreement between the instruments [12,42]. Rasch
analysis showed that although EQ5D and SF6D separ-
ately seem to have unidimensional scale properties they
probably do not measure the same underlying construct.
SF6D show less similarity with the baseline scores of the
disease specific instrument but were more responsive to
detect a change in the underlying construct in addition
to better ability to correctly diagnosing a patient as ha-
ving improved when this was really the case even though
it did not reach the level of the ODI. The MIC values
were quite different and SF6D had a better ability to
identify truly change in scale score beyond measurement
error.
Van Stel et al. showed that the EQ5D and the SF6D
yield dissimilar scores in patients with coronary heart
disease, and consequently, they cannot be used inter-
changeably [43]. This is in line with the Bland-Altman
plot pattern we found in our study and in agreement
with other previously published reports [6,13,43]. Fur-
thermore, we observed that the magnitude of difference
between the two instruments in the Bland-Altman plot
was beyond the MIC for both instruments and therefore
interpreted as clinically significant.
In this study, sensitivity was defined as the proportion
of patients that truly improved (true-positive rate), and
the sensitivity was the proportion of patients that did
not actually improve (true-negative rate). The EQ5D di-
agnosed fewer patients as clinically improved (change
score values beyond MIC). This was also reflected in the
MIC/MDC95 ratio (the proportion of patients who truly
changed with a possibility of 95% predicted by the in-
struments): For the MIC value to reach the MDC95, the
specificity for the SF6D would have to increase from
78.1 to 87.5, but the sensitivity would then fall from 92.5
to 73.7. For the EQ5D, this would necessitate an increase
in specificity from 78.9 to 86.8 and a decrease in sensi-
tivity from 72.8 to 57.6. In other words, to reach a value
beyond the 95% CI for measurement error, the probabil-
ity of correctly classifying a patient as improved would
fall dramatically for the EQ5D, nearly reaching 50% or
classifying by chance. The effect was not as dramatic for
the SF6D, which would still correctly classify over 70%
of patients as “improved”.
We found that the difference in the range of the scales
between the SF6D and the EQ5D could be reflected in
Figure 3 Person-item threshold distribution for SF6D.
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Figure 4 ROC curve.
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their targeting properties. Based on the Rasch analysis
(Figures 3 and 4), we could hypothesize that patients
were at a lower level of HRQoL than the SF6D could ex-
press (floor effect). The range of patient abilities was bet-
ter captured within the EQ5D scale. Barton et al. [6]
compared the performance of the EQ5D and the SF6D
in 1865 individuals over ≥45 years old. They found that
healthier individuals had higher scores on the EQ5D,
and less healthy individuals such as patients with back
pain had higher scores on the SF6D. In a study that
compared the SF6D and the EQ5D in liver transplant
patients, Longworth et al. observed that the SF6D does
not describe health states at the lower end of the utility
scale but is more sensitive than the EQ5D in detecting
small changes at the top of the scale [14]. This result is
somewhat confusing because the same group later pub-
lished a paper in which they conclude that the SF6D can
describe some “poor health states including states that
(according to the EQ5D scoring algorithm) are viewed
as worse than the state of being dead” [13].
The Rasch analysis also revealed that some of the
SF6D items did not function as intended. A better fit to
the model was achieved if some of the response categor-
ies of these items were collapsed (i.e., the category was
removed from the item). An interpretation of this is that
for these items, patients could not differentiate between
two adjacent response categories and the information in
the removed categories was therefore redundant. None
of the items in the EQ5D showed similar signs of dys-
function. When treated as separate scales, both instru-
ments showed signs of unidimensionality, but significant
invariance across items was noted when analyzed as one
scale (all items from the SF6D and the EQ5D put to-
gether). The interpretation of this was that the two
scales seem to measure different aspects of HRQoL.
Walters and Brazier mentioned that a fundamental as-
sumption in their comparison of the EQ5D and the
SF6D was that the instruments should measure the same
underlying HRQOL variable [44].
Strengths and limitations of the study
Compared to Brazier et al. [7], SF6D in our study had a
higher percentage of missing data at both assessment
time points (baseline and 2-year follow up). As Brazier
mentioned in another paper, this has important conse-
quences for data quality [45].
The use of global assessment score has been questioned
in several studies [46,47]. Criticism of the reliability of an-
chor based methods includes no standardization of an-
chors, time dependence of patients perception of health,
dependence on only one question and failure of the an-
chor question to differentiate between quantitative and
qualitative perception of change [48]. The COSMIN study
did not reach any consensus about which method to use
to determine the MIC value but conclude that there is an
ongoing discussion about this in the literature [23]. Some
authors now suggest ROC analysis for determining MIC
values mainly because it uses all available data and maxi-
mizes the number of individuals correctly classified [49].
The question and answer categories in our 7-point global
scale was not a standardized scale but Spearman`s rho for
the correlation between change scores of the instruments
and global score categories used in the ROC analysis was
considered acceptable (0.84, 0.55 and 0.76 for ODI, EQ5D
and SF6D respectively) [46,50,51].
Conclusions
EQ5D and SF6D measure different aspects of HRQoL.
The difference in psychometric properties between them
and the lack of agreement is probably clinically significant.
Because the ability to detect a change in the underlying
construct and similarity to a disease-specific instrument is
quite different, the choice of instrument should probably
be guided by diagnosis and/or treatment choice. In our
study of patients with chronic low back pain, the SF6D
had the best ability to detect change and correctly identify
patients as improved or non-improved beyond a 95% con-
fidence level of measurement error.
Finally, our study supports the findings of Soegaard
et al. [11]. They concluded that the SF6D and EQ5D
cannot be used interchangeably for measurement of
preference value and that sensitivity analysis examining
the impact of between-measure discrepancy remains a
necessary condition for cost-utility evaluation results.
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Appendix

APPENDIX 
Rasch analysis 
Rasch analysis is a probabilistic model that tests the extent to which the observed pattern of 
responses fits the pattern expected by the model 377 378 379. The model shows what should be 
expected in responses to items if measurement (at the metric level) is to be achieved 240. Two 
qualities are central: the ability of a person and the difficulty of an item. The ability can be any 
clinical sign, such as low back pain. The difficulty of an item could be seen as a measure of the 
extent to which a person has the ability (e.g., more or less low back pain). The model states that 
the probability that a person will affirm an item is a logistic function of the difference between a 
person’s level of, for example, reduced physical function due to low back pain (ɽ) and the level 
of reduced functional level expressed by the item (b) and only a function of that difference 240 
 
Pnij is the probability that a person n will answer in the “affirm” category j of item i (or be able to 
do the level of a task specified by that category within the item). Rasch analysis also offers the 
possibility of converting ordinal raw data into a linear scale if the data fit the model. We used a 
polytomous variant of the Rasch model, which is known as the partial credit model 380. 
In PCA, we explore the relationship of the items to the components that contribute most to the 
variation in data after the Rasch component is removed293. This is done by comparing fit 
residuals for each person for each item using independent t-tests 292. The first component in the 
PCA is the component that accounts for the most variance in the data and can be seen as a 
“second dimension.” To examine this, we used the subsets of items that loaded the most 
strongly on the first component because these were the most likely to breach the assumption of 
unidimensionality. In other words, if these two subsets showed a significant difference from the 
overall scale, then the assumptions of unidimensionality could be broken. If the data fit the 
model, then analysis of any subsets of items should produce equivalent person measures within 
measurement error. 
Threshold order 
A threshold is defined as the 0.5 probability point between adjacent categories of an item240. The 
probability of affirming one category response is illustrated by probability density curves for 
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each of the categories (fig 6). The 0.5 probability is then at the top of the curve. For categories in 
increasingly or decreasingly order the top of curve 1 should come before curve 2, the top of 
curve 2 should come before curve 3 etc. When this is not the case, the thresholds are disordered 
(fig 7 ). For SF-6D, disordered thresholds were found between category 3 and 4 in “Physical”, 
between category 2 and 3 in “Role” and between category 1 and 2 in “Pain”.  
 
 
Figure6. Example of item with ordered thresholds 
  
 
 
 
Figure7. Example of item with disordered thresholds 
 

